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ABSTRACT 
 
Role of the Leucine Zipper of Marek’s Disease Virus Oncoprotein Meq in Pathogenesis. 
(May 2009) 
Paulette F. Suchodolski, B.S.; M.S., Texas A&M University 
Chair of Advisory Committee: Dr. Sanjay Reddy 
 
Marek’s disease virus (MDV), the etiologic agent of Marek’s disease, is a potent 
oncogenic herpesvirus.  MDV is highly contagious and elicits a rapid onset of malignant 
T-cell lymphomas in chickens within several weeks after infection.  The MDV genome 
encodes an oncoprotein, Meq, which shares resemblance with the Jun/Fos family of 
bZIP transcription factors. Similar to c-Jun, the leucine zipper region of Meq allows the 
formation of homo- and heterodimers. Meq homo- and heterodimers have different DNA 
binding affinities and transcriptional activity; therefore, they may differentially regulate 
transcription of viral and cellular genes. Previous in vitro data has suggested that Meq 
homodimers may be involved in regulating viral latency/reactivation, while Meq/c-Jun 
heterodimers are involved in transformation. Therefore, this research investigates the 
role of Meq homodimers and Meq-Jun heterodimers in the pathogenicity of MDV, by 
generating chimeric meq genes, which contain the leucine zipper region of the yeast 
transcription factor GCN4 (meqGCN) or leucine zipper region of c-Fos (meqFos). Thus 
producing Meq proteins that exclusively homodimerize (MeqGCN) or heterodimerize 
with Jun family members (MeqFos). Recombinant viruses (rMd5-MeqGCN and rMd5-
 iv 
MeqFos) containing the chimeric genes meqGCN or meqFos, respectively, in place of 
parental meq were generated with overlapping cosmid clones of Md5, a very virulent 
MDV strain.  The chimeric genes were evaluated in vitro and retained DNA binding and 
transactivation/repressive functions, however, selected cells expressing MeqGCN and 
MeqFos had reduced colony formation in soft agar. Both the rMd5-MeqGCN and rMd5-
MeqFos viruses replicated in vitro and in vivo, but rMd5-MeqGCN was unable to 
transform T-cells in infected chickens, while rMd5-MeqFos induced preneoplastic nerve 
lesions in 50% of infected birds. However, a third virus rMd5-MeqFos/GCN, which 
contains one copy of each meqGCN and meqFos, induced preneoplastic nerve lesions in 
60% of infected chickens and neoplastic lesions in 20% of infected chickens. These data 
provide the first in vivo evidence that both Meq homodimers and heterodimers are 
necessary for MDV induced transformation. 
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CHAPTER I 
INTRODUCTION 
 
Marek’s disease 
 Marek’s disease (MD) is a highly contagious and oncogenic cell-associated 
herpesvirus, of the genus Mardivirus that causes lymphoproliferative and neuropathic 
disease in chickens. MD was first described in 1907 and is named in honour of the 
Hungarian veterinarian Jozsef Marek, who first described the disease as fowl paralysis 
(polyneuritis). Early descriptions of MD indicated the disease only affected the nervous 
system. However, in the 1920’s, significant proportions of affected chickens also had 
visceral lymphomas, which were cytologically similar to the lymphoid infiltrations in 
nervous tissue. These occurrences of visceral tumors in MD lead to confusion with 
lymphoid leukosis (6). Leukosis describes proliferative diseases of the haemopoietic 
system caused be avian leukosis virus (ALV), and lymphoid leukosis is the most 
common form (59).  Since distinguishing between MD tumors and lymphoid leukosis 
relied on pathological examination confusion on distinguishing these two etiologies 
continued and as a result the view that all lymphoid tumors were an indication of a 
single disease was common.  It was not until 1960 that the World Veterinary Poultry 
Association called for a conference to classify Avian Leukosis Complex and fowl 
paralysis. At the end of the conference it was recommended that the two diseases be  
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distinguished and that “fowl paralysis” be termed MD (6). 
 During the 1950’s explosive outbreaks of “visceral lymphomatosis” in addition 
to neural involvement became prevalent in the USA and Europe, this new form of MD 
was termed acute MD, young chickens were affected with mortality of 20-30% on 
average but as high as 60% (6). In addition to higher mortality, acute MDV strains have 
a higher incidence of visceral tumors compared to classical strains (89). By the 1960’s 
acute MD was widespread and predominate in countries with a developed poultry 
industry. Vaccination was introduced in the 1970’s and controlled MD well, however in 
the late 1970s and again in the 1990’s new vaccine strategies were implemented to 
circumvent vaccine breaks (6). MD is an economically important disease of poultry and 
is controlled by vaccination to prevent economic losses by highly contagious and 
potently transforming MDV. In 2007 it was estimated that over 10 billion chickens in the 
United States alone were vaccinated against MD (69). 
 Three serotypes of MDV have been identified based on virus neutralization and 
agar gel precipitation analysis and are currently classified as Gallid herpesvirus 2 
(GaHV-2) or Marek’s disease virus serotype 1 (MDV-1), Gallid herpesvirus 3 (GaHV-
3) or Marek’s disease virus serotype 2 and the Meleagrid herpesvirus 1 (MeHV-1) or 
turkey herpesvirus, only MDV-1 is oncogenic. In addition, a number of different 
pathotypes exist within MDV-1 ranging from mild to very virulent plus (12, 88). 
Vaccination with non-oncogenic turkey herpesvirus, HVT, was introduced in the 1970’s 
and provided excellent protection, however, due to interference with maternal antibodies 
and increased virulence from field strains, a bivalent vaccine was introduced in the mid 
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1980’s. The bivalent vaccine combined HVT and the non-oncogenic SB-1, MDV 
serotype-2 and provided better protection than either component alone. Still, vaccine 
breaks continued and the emergence of more virulent field strains emerged, and in the 
1990’s the Rispens vaccine was introduced. Rispens is a tissue culture attenuated MDV-
1 virus strain called CVI988 (3). The Rispens strain is the most widely used and the most 
effective MDV vaccine available today. A number of different pathotypes exist within 
MDV-1 ranging from mild to very virulent plus (12, 88).  It is believed that the 
continued emergence of virulent pathotypes in MDV is a consequence of vaccine 
pressure (69). Development of new vaccines with increased efficacy continues to be 
explored in anticipation of the emergence of more virulent strains. The most current 
potential vaccine is a recombinant MDV-1 strain in which the putative oncogene Meq 
has been deleted from the genome and results in higher efficacy than the current Rispens 
vaccine (39).  
 
Pathogenesis of Marek’s disease infection 
  There are three main phases of MDV infection: cytolytic, latent and transforming 
infection. Lesions associated with MDV include inflammatory lesions during cytolytic 
infection, and proliferative lesions, which are composed of transformed T-cells. 
Transformed T-cells can be found in nerves or visceral organs (7, 12). It is the 
infiltration and proliferation of T-cells in the nerves that causes paralysis and the 
classical disease. Proliferative lesions in the visceral organs in addition to the nerves are 
associated with acute MD and increased virulence (89). 
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Cytolytic infection 
Initial infection occurs through the respiratory tract by inhalation of dander 
containing infectious virus. It is presumed that phagocytic cells pick up virus in the lung 
and then distribute it to bursa of Fabricius, spleen and thymus. This begins the early 
cytolytic phase of MDV infection in which virus is produced and released resulting in 
cell death and necrosis and is evident 3-6 days PI. B-cells are the primary target cell 
during cytolytic infection, this has been demonstrated by in vitro infection of splenocytes 
and embryonal bursectomy, which results in impaired cytolytic infection. But, lytic 
infection has been detected in activated CD4+ and CD8+ T-cells (12). Interestingly, 
MDV infection of macrophages from infected chickens has been demonstrated by viral 
antigen detection using flow cytometric analysis and confocal microscopy, thus 
supporting a role for macrophages as the carrier cells during initial infection. However, 
since the presence of viral particles was not detected, further work is needed to evaluate 
if macrophages can maintain productive infection (4). In addition to lymphocytes, 
epithelial cells are highly susceptible to cytolytic infection and infection of non-
lymphoid cells have been found in multiple organs including, kidney, adrenal gland, 
proventriculus, lung, liver, and crop to list a few (12). A consequence of cytolytic 
infection is atrophy of thymus and bursa of Fabricius, which is more evident with more 
virulent pathotypes (14, 70). Cytolytic infection plays an important role in the spread of 
MDV infection, activation of the immune system and therefore number of target cells 
available for MDV transformation (12). This has been demonstrated in mutant 
recombinant viruses that had impaired cytolytic infection and reduced tumor induction 
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(18, 25, 32, 57). The feather follicle epithelium is the only site of fully productive 
infection in which infectious cell free virus is produced. It has been suggested that 
virulence and transmission are interrelated traits, however this has not yet been 
quantitatively assessed (69).   
 
Latent infection 
A feature of all herpesviruses is the ability to enter a latent state in their natural 
hosts. During latency the viral genome is maintained and only a small set of proteins or 
viral RNA are expressed, and infectious virus is not produced (78). Immune responses to 
herpesvirus infection play an important role in the switch from cytolytic infection to 
latency.  Approximately 7-8 days PI, cytolytic infection switches to a non-productive 
latent infection during which viral proteins are not expressed. Immunocompetence 
influences the switch to latency and is required for maintenance of latency.  
Immunosuppressive treatments of infected chickens leads to prolonged cytolytic 
infection and recrudescence of cytolytic infection after latency has been established (9). 
Although not defined, extrinsic factors influence the switch to latency (12). Recombinant 
IFN gamma combined with lipopolysaccharide (LPS), and nitric oxide treatment reduce 
MDV and HVT replication in vitro. Cytotoxic T-cell (CTL) responses against MDV 
lytic antigens, ICP4, pp38, gB have been demonstrated which may also drive the switch 
to latency for the virus to “escape” immune surveillance (71). In contrast to cytolytic 
infection, activated CD4 + T-cells are the predominate cell type infected during latency. 
The difference in cell type infected during latency and cytolytic infection may be a 
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consequence that B-cells are shorter lived or that T-cells are intrinsically less able to 
support productive infection (12).  
 
Transforming infection 
 Activated CD4+ T-cells are the target cell for MDV transformation. MATSA 
(Marek’s disease tumor associated surface antigen) originally described in MD tumor 
cells as an MDV specific marker was later found to be a marker of activated T-cells, and 
another MD tumor associated marker AV37 is also likely linked with an activated 
phenotype. The important role of immune activation in transformation has been 
demonstrated in a study by Calnek et al. (1989), in which alloantigens along with MDV 
were injected in wing webs and enhanced tumor development was observed. Current 
knowledge of lymphoma development in MDV entails a series of sequential events that 
lead to MDV transformation, the first being the initial cytolytic infection, followed by a 
period of latency, and eventually transformation. The necrotizing infection and 
inflammatory response that develops during cytolytic infection plays an important role in 
stimulating the activation of T-cells and recruitment of target cells and the switch to 
latent infection Lymphomas may be found in any visceral organ, peripheral nerves, eye 
and skin as early as 12-14 PI with highly virulent pathotypes (12). Like latently infected 
cells, transformed cells do not produce infectious virus. In addition, few known viral 
antigens are expressed.    
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MDV genome and genes associated with pathogenesis 
The180 kb linear double-stranded DNA genome of MDV is surrounded by a 100 
nm icosahedral protein capsid core. The tegument, is a proteinaceous structure that 
varies in thickness and surrounds the capsid core, a lipid envelope in turn surrounds the 
tegument and core. Enveloped virus varies in size from 120 to over 300 nm in diameter 
depending on the thickness of the tegument and state of the lipid envelope. Although, 
MDV shares biological characteristics with gammaherpesviruses such as its tropism and 
its ability to transform lymphocytes, it is classified as an alphaherpesvirus based on viral 
genome organization and sequence homology (67). The genome structure consists of 
unique long (UL) and short (US) regions flanked by terminal and inverted repeat long 
(TRL, IRL) and terminal and inverted repeat short (TRS, IRS).  
 
Search for MDV oncogene(s) 
The highly oncogenic nature of MDV suggests the viral genome encodes 
oncogene(s). Initial investigations in the search for candidate viral oncogenes focused on 
transcriptionally active regions of the MDV genome, genes expressed in transformed 
cells, and identification of genes unique to MDV. In MDV transformed cells 
transcription is limited to the repeat regions whereas in lytically infected cells 
transcription throughout the viral genome is detected. Probes from BamH1 and partial 
EcoQ libraries were used to screen genes expressed in MDV lymphoblastoid cells.  
Transcription was found to be limited to repeat regions with the highest transcription 
from Bam I2 and EcoQ regions with most transcripts originating from the EcoQ region. 
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Therefore, the EcoQ region was sequenced and a predicted protein coding sequence that 
shared homology with the bZIP factors, c-Jun and c-Fos, was found and named Meq. 
The meq gene is named after the EcoQ fragment where it is located, “Marek’s EcoQ”, 
and two copies are found in the viral genome within the terminal repeat long (TRL) and 
internal repeat long (IRL) regions (60, 66, 67, 80). Antibodies raised against the leucine 
zipper region of Meq were successful in detecting 40 and 60 kda proteins from the MDV 
transformed cell line RP4 (33). Since c-Jun and c-Fos are proto-oncogenes (73), the 
shared homology of Meq with these factors and detection of Meq in tumor cells lines, 
suggested a role for Meq in MDV transformation.  
While MDV pp38 and ICP4 genes are also located in transcriptional active 
regions of MDV transformed cells, only Meq is consistently expressed in tumor cells 
and unique to the oncogenic MDV-1 genome (33).  Although, pp38 expression has been 
identified in MDV transformed cells, because pp38 is a lytic associated protein, it is 
commonly argued this represents a subset of cells undergoing reactivation. In addition, 
only anti-sense transcripts to ICP4 have been identified in transformed cells (43, 44).  
 
Meq 
  After the identification of Meq several studies soon followed to characterize this 
unique MDV putative oncogene. Meq is a bZIP protein with a basic DNA binding 
domain at the N+ terminus, leucine zipper, and proline rich C+ terminal transactivation 
domain (33). Meq is a nuclear phosphoprotein and potentially phosphorylated by a 
number of cellular kinases, including PKA, PKC and MAPK (49). Nuclear and nucleolar 
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localization signals are located in the basic region, and referred to as BR1 and BR2, 
respectively (46). A proline/glycine rich region is located adjacent to the basic region 
that contains a C-terminal binding protein (CtBP) site (8). In addition Meq contains 
putative p53 and retinoblastoma (Rb) binding sites (45). The proline rich domain of Meq 
is a potent transactivator with the last 33 amino acids essential for transactivation (62).   
The DNA binding and transactivation/repression properties of Meq have been 
investigated to better understand Meq’s potential role as a transcriptional regulator. The 
cyclic amplification of selected targets (CASTing) technique using bacterial expressed 
Meq amino acids 1-129 and c-Jun proteins were utilized to determine the optimal DNA 
binding sites of Meq/c-Jun and Meq/Meq dimers. Meq/c-Jun heterodimers were found to 
bind tetradecanoylphorbol acetate response element (TRE; TGAGTCA) and cyclic AMP 
response element (CRE; TGACGTCA) core containing sequences RTGAC(G)TCAY 
where R is a purine and Y is a pyrimidine referred to as Meq response element 
(MERE1). Meq/Meq homodimers bound an extended MERE I sequence 
GAGTGATGAC(G)TCATC and consensus sequence RACACACAY (MERE II). 
However, MERE II sequences are necessary, but not sufficient, for Meq binding, and 
additional flanking sequences are required for binding by Meq. EMSA analysis further 
demonstrated Meq/c-Jun heterodimers bind TRE and CRE sequences but Meq 
homodimers only bound MERE II like sequences (61). The meq promoter contains a 
CRE/TRE like sequence (TGACGT) and therefore potential Meq binding site. 
Luciferase assays confirmed that Meq transactivates the meq promoter, and transfections 
together with c-Jun resulted in increased activation (47, 61). The MDV pp38/14 
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bidirectional promoter contains a sequence (ACACA) that resembles MERE II at the 
MDV Origin of replication, with which Meq homodimers were shown to bind by EMSA 
(42, 61). However, unlike the meq promoter, Meq repressed both pp14 and pp38 
promoters in a dose dependent manner (42). A modified ChIP assay was performed to 
evaluate Meq binding sites in the MDV genome. Cross-linked sonicated chromatin was 
recovered from MSB1 cells, an MDV transformed cell line, followed by 
immuoprecipitation with Meq or c-Jun specific antibody. The recovered DNA fragments 
were labeled with radioactive P32 and used to probe digested cosmid DNA spanning the 
MDV genome. The results indicated numerous low affinity Meq binding sites were 
present throughout the MDV genome, with areas of higher affinity. Based on restriction 
enzyme maps, these areas of high Meq binding corresponded with the meq and ICP4 
promoters as well as the MDV Ori. PCR analysis from ChIP samples confirmed Meq 
was recruited to each of these promoters and the MDV gB promoter as well. In addition, 
PCR analysis from ChIP samples immunoprecipitated with c-Jun antibody showed that 
c-Jun was recruited to the Meq and ICP4 promoters. Gel shift assays, 
coimmunoprecipitation and ChIP assays have confirmed dimerization of Meq and c-Jun 
in vitro and in MDV transformed cells (42). Considering the oncogenic potential of c-
Jun, a role between c-Jun and Meq in MDV transformation is appealing. 
Expression of Meq in vitro supports its oncogenic potential. Meq has been shown 
to promote anchorage independent growth in rat-2, and DF-1 cell lines (41, 47, 48). 
Expression of Meq also promotes resistance to apoptosis under serum deprivation and 
treatments with ceramide, TNFα, and UV (48). Meq is essential for T-cell 
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transformation in vivo, as deletion of Meq from the MDV genome and mutations of the 
CtBP site have been shown to result in loss of transformation (8). However, the 
molecular mechanisms of Meq in MDV transformation remain to be defined, recent 
studies indicate Meq/c-Jun partnership may play a critical role in MDV transformation. 
Expression of Meq in DF-1 cell line was shown to activate genes associated with the v-
Jun pathway, such as HB-EGF, Bcl-2, JTAP-1, and JAC. In addition silencing of c-Jun 
by siRNA resulted in reduction in colony formation induced by Meq expression (41).   
 
Other MDV genes associated with pathogenesis 
A number of genes unique to MDV are encoded within the repeat long region or 
at its junction with the unique long region, and have been associated with pathogenesis. 
These genes include pp38, v-IL8, and LORF11 genes. Disruption of these genes from 
oncogenic MDV has been shown to result in reduced tumor incidence. This is likely a 
consequence of impaired lytic replication in chickens rather than a direct role in 
transformation (17, 25, 40, 57). The pp38 gene encodes for an MDV lytic antigen that is 
evident during cytolytic infection of lymphoid tissues. Although, pp38 may be detected 
in subsets of cells from MDV transformed cells this may represent virus undergoing 
reactivation. The MDV virokine, v-IL8, shares significant homology with cellular CXC 
chemokine IL-8. And bacterial expressed v-IL8 functions as a chemoattractant for 
chicken peripheral blood mononuclear cells. A reduction in tumor incidence in vivo is 
evident with v-IL8 deletion mutants, however cytolytic infection is also impaired, 
therefore v-IL8 deletion mutants may indirectly impair tumor formation by reducing 
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transformable target cells (18, 57). LORF-11 is an MDV unique gene of unknown 
function present in oncogenic and non-oncogenic MDV serotypes.  Deletion of LORF-
11 from the MDV genome resulted in a virus that was able to replicate in vitro but was 
replication defective in vivo. Antigen detection in lymphoid organs was not detectable at 
6 days PI. Therefore, although no tumor incidence was observed in chickens infected 
with a rMd5ΔLORF-11 this is likely a consequence of absent viral replication (40).  
However, disruption of viral telomerase RNA (vTR) or meq genes from the MDV 
genome does not disrupt early cytolytic infection, but greatly reduces or abolishes tumor 
incidence, respectively (50, 79). The MDV-1 genome encodes a functional vTR which 
shares 88% homology with chicken telomerase (chTR) and is not found in the non-
oncogenic MDV-2 or MeHV-1 genomes (23). In vitro expression of vTR in cells 
significantly enhanced proliferation compared to vector control cells and more 
importantly deletion of vTR from the MDV genome resulted in a 60% reduction of 
tumor incidence in infected chickens (79).  
 
bZIP- proteins 
Basic leucine zipper (bZIP) proteins are a group of transcription factors that 
consist of a basic DNA binding region adjacent to a leucine zipper region and have been 
described in plants, insects, and mammals. The sequences of bZIP proteins widely vary 
but the leucine zipper and basic domain are the common features of this group. The 
location of the bZIP domain also varies and can be located at either the N+ or C+ 
terminus. The DNA binding domain is the most conserved region among bZIP proteins 
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and contain the consensuses sequence, N _ _ A _ _ (C/S) R, ending just before the start 
of the leucine zipper.  The leucine zipper region is less conserved but all consist of a 
periodic repeat of a leucine every 7th amino acid, however in some proteins one or more 
of the leucine residues may be replaced by an alternative amino acid. The number of 
leucine repeats also varies among bZIP proteins and three up to six repeats have been 
described. Although the sequences of bZIP proteins vary greatly, a high degree of 
homology across species for a given bZIP exists (19). The importance of bZIP proteins 
across species is evident, as these factors have been described in a broad range of 
cellular functions. In mammals, bZIP factors have a critical role in cell proliferation and 
development of liver, bone and heart during embryogenesis. They are also involved in 
metabolism, and stress response in mammals (19, 21). In plants bZIP proteins are 
involved in regulating seed development and flower maturation, and sexual maturation 
in yeast (19).  
The main function of the leucine zipper is to bring the basic regions of each 
monomer together to allow for specific DNA binding. Characterization of the function of 
the leucine zipper in dimerization has been carried out with the bZIP proteins c-Jun, c-
Fos, and GCN4. Experiments were performed by generating chimeric bZIP proteins by 
swapping the leucine zipper region and testing dimer formation by EMSA anaylsis (37, 
72). The results conclude that the leucine zipper region is interchangeable and dictates 
whether a bZIP protein will form homodimers or heterodimers. It was demonstrated that 
the leucine zipper region of c-Jun allows for the formation of both homodimers and 
heterodimers while the leucine zipper regions of GCN4 and c-Fos exclusively confers 
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homodimerization and heterodimerization, respectively (37, 72).  The seven amino acids 
of each repeat are denoted as a-g and the residues in the opposite dimer a′-g′. Leucine 
residues are found at position d. Position a contains hydrophobic residues a 
characteristic of coil-coil structures, and most charged residues occur at positions e and 
g. The charges of the amino acids at the e and g position have been shown to be 
important determinants of homodimerization and heterodimerization. For example, 
proteins where the e and g residues within one heptad are of opposing charge can form 
both homo- and heterodimers, whereas, e and g residues of the same charge will form 
heterodimers with a protein with e and g residues of opposite charge (30).  
DNA binding sites recognized by bZIP dimers show dyad symmetry, or two 
“half sites” which are contacted by each of DNA binding domain in the dimer. 
Activating protein-1 (AP-1) transcription factors are a group of well-described bZIP 
proteins that are characterized by their ability to bind and regulate sequence specific 
gene elements, AP-1, which are found in many genes associated with cell proliferation 
(73). The c-Jun, c-Fos, and CREB/ATF families are part of the AP-1 complex. The 
consensus sequences recognized by AP-1 factors are TPA-response element (TRE) 
TGAGTCA and cyclic AMP response elements (CRE) TGACGTCA.  However, it is 
important to keep in mind since that since optimal binding site are evaluated in vitro, 
target sequences in natural promoter or enhancer settings may deviate from the optimal 
recognition sequence (16). It is well established that dimerization impacts the sequences 
that bZIP proteins bind. For example, as homodimers the Fos/Jun families preferentially 
bind TRE sequences while the CREB/ATF family preferential bind CRE sequences. In 
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addition, as heterodimers DNA binding preferences and affinity may change.  For 
instance, c-Jun/c-Fos heterodimers recognize TRE sites, while c-Jun/ATF2 dimers 
preferentially bind CRE sequences and even though Jun/Jun homodimers bind TRE 
sites, c-Jun/c-Fos heterodimers bind TRE sites with greater affinity (26, 81). While it is 
generally accepted that most bZIP proteins dimerize before DNA binding, some bZIP 
proteins including c-Fos and c-Jun can bind DNA as monomers and then dimerize. In 
addition, specificity of DNA binding is dependent on the basic region and the spacer 
region located between the basic region and leucine zipper (82). For example, domain 
swapping experiments have shown that although the leucine zipper region dictates 
dimerization therefore impacting DNA binding preference, DNA binding is still 
influenced by the basic regions. Chimeric proteins containing c-Fos or c-Jun basic and 
leucine zipper domains can form stable heterodimers and bind AP-1 probes designed 
from the Jun promoter. However, chimeric proteins with the CREB basic region and c-
Jun or c-Fos leucine zipper domains have reduced DNA binding even though 
dimerization through the c-Fos and c-Jun leucine zipper region is intact (63).  
In addition to the bZIP domain, nuclear localization signals, and activation and 
repression domains are also typically found in bZIP proteins and contribute to their role 
as transcriptional regulators. Nuclear localizations signals are generally found in the 
basic domain of bZIP proteins and ensure transfer to the nucleus. Activation and 
repression domains contribute to the regulatory activity of bZIP proteins, which are in 
turn regulated by phosphorylation. In addition AP-1 members regulate each other, for 
instance Jun promotes cell proliferation while JunD and JunB are negative regulators of 
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cell proliferation (21).  The ability of cross dimerization between bZIP members results 
in a cell specific competition for dimerization partners and DNA binding sites that 
results in a complex system of transcriptional regulation (82). In addition, the activity of 
bZIP proteins are further regulated by phosphorylation, that depends on the activated 
kinases present in a particular cell. Therefore, overexpression of AP-1 members, 
mutations or deletions in regulatory domains such as in v-Jun lead to deregulated 
transcription and transformation.  
 
c-Jun 
The viral counterpart of c-Jun, v-Jun, was first cloned from the avian sarcoma 
virus 17 in 1987 and Jun was later identified as the cellular homologue of v-Jun and a 
component of AP-1. In fact, the name “jun” is derived from the Japanese word ju-nana, 
meaning 17 (85). The connection of c-Jun and AP-1 came about after the homology 
between c-Jun and GCN4 was recognized. AP-1 proteins were initially recognized as a 
TPA inducible transcription factor(s) that bound specific elements in the metallothionein 
gene and 72 base pair repeat in the SV40 enhancer region, because it was known that 
GCN4 also bound AP-1 sequences, Jun was discovered to be a component of AP-1 (84).  
A 27 amino acid (delta) deletion and two to three amino acid substitutions 
(depending on the clone) are found in v-Jun compared to c-Jun. The delta deletion 
results in deletion of the Jun-N-terminal Kinase (JNK) binding site found in Jun. JNK 
phosphorylation of Jun results in transcriptional activation by weakening the interaction 
with the histone deacetylase (HDAC-3) inhibitor complex. Even though v-Jun is not 
 17 
activated by JNK, it is a strong transactivator because it is relieved of inhibition from the 
HDAC-3 inhibitor complex.  Another mechanism in which v-Jun escapes negative 
regulation is due to a phosphorytaion mutation at position 243. In c-Jun serine 243 is 
phosphorylated by ERK, which in turn promotes phosphorylation of threonine 239 by 
GSK-3. Phosphorylated threonine 239 provides an attachment site for Fbw7 ubiquitin 
ligase and subsequent proteasomal degradation of c-Jun (86).  
A number of studies have been performed in order to understand the 
transformation pathway of c-Jun and delineate the function of c-Jun homodimers and 
heterodimers. To study Jun homodimers in transformation chimeric c-Jun proteins with 
the leucine zipper of EB1 or GCN4 were utilized. Chimeric c-Jun homodimers proteins 
were able to transform CEF as assessed by proliferation in reduced serum and anchorage 
independent growth, thus supporting that Jun homodimers promote transformation. 
However, chimeric c-Jun proteins did have reduced colony formation compared to wild 
type morphologically had a more condensed than elliptical appearance (15). A similar 
study using chimeric c-Jun homodimers was performed but with v-Jun. The chimeric v-
Jun proteins also induced anchorage independent growth; with reduced numbers 
compared to v-Jun. Interestingly in vivo the v-Jun-GCN4 construct was similar to v-Jun 
while v-Jun-EB1 was more oncogenic (34). However, it should be noted that the 
described chimeric c-Jun proteins are more stable than wild type c-Jun/c-Jun 
homodimers and can bind AP-1 sites with affinity comparable to c-Jun/c-Fos dimers. 
Van Dam investigated the role of c-Jun/c-Fos and c-Jun/ATF heterodimers by generating 
point mutations in the leucine zipper region that resulted in Jun proteins that showed a 
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preferred dimerization with c-Fos or ATF2. Using these constructs he demonstrated that 
c-Jun/c-Fos dimers promoted anchorage independent growth while c-Jun/ATF2 dimers 
promoted growth factor independence (81). Together, these studies show that 
homodimerization and cross dimerization contribute to transformation.   
 
Unique viral bZIP proteins 
Only two other bZIP proteins encoded by herpesviruses have been described, 
Zta, (also known as ZEBRA, or EB‐1) from Epstein barr virus (EBV) and K-bZIP (also 
known as (RAP, or K8α) from Kaposi sarcoma associated virus (KSHV). However, both 
Zta and K-bZIP differ from typical bZIP proteins in that the dimerization domain of Zta 
is weak compared to other bZIP proteins, and K-bZIP does not contain a basic DNA 
binding domain. Zta and K-bZIP are expressed during lytic infection but are silent 
during latency. Expression of Zta is sufficient to disrupt latent infection, however this 
does not apply to K-bZIP. Zta functions as transcription factor and activated early viral 
gene transcription and can repress transcription of viral late genes. In addition to 
regulation of viral gene transcription Zta also binds to the origin of lytic replication 
(oriLYT) and is necessary for lytic replication by recruiting and interacting with viral 
proteins essential for viral replication. In contrast K-bZIP does not activate transcription 
of viral early genes but is necessary for viral replication (75).  
Cellular proteins that have been described to interact with Zta and K-bZIP 
include p53, CREB-binding protein (CBP), C/EBPα, and TATA binding protein (TBP). 
The bZIP region of both Zta and K-bZIP interact with the C-terminal region of p53 and 
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can interfere with p53 dependent transcription (58, 75).  However, activation and 
enhancement of p53 by Zta in some cell lines has also been described and leads to cell 
cycle arrest. Interactions of Zta and with the co-activator CBP enhances transcriptional 
activity of Zta and can relieve K-bZIP mediated repression. The C-terminal domains of 
both Zta and K-bZIP interact with the bZIP transcription factor C/EBPα leading to 
enhanced expression of cyclin-dependent kinase inhibitor, p21CIP1, which also promotes 
cell cycle arrest (5, 75). Lastly, Zta has also been shown the interact directly with TBP 
and stabilizes the association of TFII with the TATA element and therefore promotes 
transcription from genes with Zta response elements (ZRE) but it is unclear if Zta 
promotes transcription from ZRE less promoters (75).  
EBV also encodes an atypical bZIP protein EBNA3C that contributes to EBV 
transformation. Although, EBNA3c contains a bZIP domain both the basic and leucine 
zipper domains do not share homology with previously described bZIP proteins. In 
addition EBNA3c specific DNA binding sequences have not been defined and it is 
unclear if EBNA3c can bind DNA directly, but EBNA3c interacts with the transcription 
factor, RBP-Jκ α, which likely directs DNA binding (87). Still, EBNA3c is a potent 
repressor and interacts with cellular co-repressors, HDAC 1, and CtBP. The 
transforming properties of EBNA3c are linked to disruption of cell cycle checkpoints 
and cell cycle progression. EBNA3c is able to disrupt the cell cycle checkpoints through 
it’s interaction with Rb, CtBP, and cyclin A (87). In addition EBNA3c has been shown 
to cooperate with H-Ras in transformation of Rat-2 fibroblasts, and is necessary for the 
growth and maintenance of lymphoblastoid cells (51).  
 20 
Human T-cell lymphotropic virus (HTLV-1) (HTLV-1) encodes the bZIP protein 
HBZ which interacts with CREB, c-Jun, JunB and JunD. Unlike v-Fos, and v-Jun, HBZ 
is a unique viral protein and not a viral homologue of a cellular factor. HBZ together 
with CREB mediates transcriptional repression of the viral oncoprotein Tax.  It is 
postulated that down regulation of Tax may be a mechanism to down regulate immune 
responses targeting Tax. In addition, HBZ attenuates AP-1 transcription by disrupting 
DNA binding through it’s interaction with JunB and c-Jun.  Although HBZ is not 
necessary for transformation of T-cells in culture, HBZ contributes to T-lymphocyte 
proliferation in vivo, however the molecular mechanism remain to be defined (2). 
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CHAPTER II 
HOMODIMERIZATION OF MAREK’S DISEASE VIRUS ENCODED MEQ 
PROTEIN IS NOT SUFFICIENT FOR TRANSFORMATION OF 
LYMPHOCYTES IN CHICKEN* 
 
Introduction 
  Marek’s disease virus (MDV), the etiologic agent of Marek’s disease, is a potent 
oncogenic herpesvirus which elicits a rapid onset of malignant T-cell lymphomas in 
chickens within several weeks of infection, resulting in mortality. MDV is classified as 
an alphaherpesvirus based on viral genome organization and sequence but shares 
biological characteristics with gammaherpesviruses such as its tropism and its ability to 
transform lymphocytes (67). Of the previously described serotypes of MDV, now 
classified as Gallid herpesvirus 2 (GaHV-2) or Marek’s disease virus serotype 1 (MDV-
1), Gallid herpesvirus 3 (GaHV-3) or Marek’s disease virus serotype 2 and the 
Meleagrid herpesvirus 1 (MeHV-1) or turkey herpesvirus, only MDV-1 is oncogenic. In 
addition, a number of different pathotypes exist within MDV-1 ranging from mild to 
very virulent plus (12, 88).  
 The search for candidate viral oncogenes in the MDV genome led to the 
discovery of meq, which is abundantly expressed in MDV transformed cells, and is  
                                                
* Reprinted with permission from “Homodimerization of Marek’s Disease Virus-Encoded Meq Protein Is 
Not Sufficient for Transformation of Lymphocytes in Chickens” by Paulette F. Suchodolski, Yoshihiro 
Izumiya, Blanca Lupiani, Dharani K. Ajithdoss, Oren Gilad, Lucy F. Lee, Hsing-Jien Kung, and Sanjay 
M. Reddy, 2009. Journal of Virology,Vol. 83 , 859-869, Copyright [2009] by American Society for 
Microbiology. 
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encoded only by the genome of MDV-1. The meq gene is named after the EcoQ  
fragment where it is located, “Marek’s EcoQ”, and two copies are found in the viral  
genome within the terminal repeat long (TRL) and internal repeat long (IRL) regions (60, 
66, 67, 80). Meq, a 339 amino acid nuclear phosphoprotein, is a bZIP (basic-region 
leucine zipper) protein, which shares significant homology, in the bZIP domain, with the 
protooncogene c-Jun a transcription factor of the AP-1 (activating protein) complex (33, 
46, 49). AP-1 transcription factors are a group of well-described proteins that are 
characterized by their ability to bind and regulate sequence specific gene elements, AP-1 
sites, which are found in many genes associated with cell proliferation (73). 
Transformation by deregulated expression of c-Jun or its viral counterpart v-Jun, is well 
documented and therefore the shared homology between Meq and Jun is intriguing (84).  
In vitro data support the oncogenic nature of Meq, which can promote 
anchorage-independent growth, cell-cycle progression, and anti-apoptosis (48, 49). 
Recently in vitro expression of Meq was shown to upregulate genes similar to those 
upregulated by v-Jun suggesting that Meq transforms via a v-Jun transforming pathway 
(41). In addition, knockdown of c-jun diminishes Meq’s transforming ability in vitro, 
strongly suggesting that Meq-Jun partnership plays a key role in Meq’s oncogenic 
potential. Yet, the most convincing evidence for Meq’s oncogenic property was the 
characterization of a Meq null recombinant MDV virus (rMd5∆Meq) which replicated in 
chickens and did not induce tumors (50). Significantly, the Meq null virus also provided 
better protection than currently available vaccines in chickens, upon challenging with the 
most virulent strains of MDV (39) pointing to a potential strategy for further vaccine 
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improvement, where more subtle mutation(s) of Meq are engineered, to abolish its 
transforming ability, while retaining its ability of establishing infection in vivo and 
associated antigenicity. To this end, it is important to further dissect the transforming 
and replication functions of Meq, which at present, remain largely unexplored.  
Like c-Jun, the leucine zipper region of Meq allows the formation of homodimers 
and heterodimers (42). It has been shown that dimerization partners of bZIP proteins are 
important determinants of DNA binding specificity and therefore transcriptional 
regulation. For example, different Jun dimers have been shown to play distinct roles in 
transformation, i.e. anchorage or serum independent growth (84). Again, similarly to c-
Jun, the DNA binding properties of Meq depend on its dimerization partner. Previous 
characterization of the in vitro DNA binding properties of Meq revealed Meq/c-Jun 
heterodimers bind AP-1 sequences, while Meq homodimers in addition to AP-1 
sequences also bind sequences found at the MDV origin of replication (Ori) (42, 61). 
Transcriptional analysis of Meq on the AP-1 containing meq promoter, and the MDV 
pp14/38 bidirectional promoter which contains the MDV Ori, revealed that Meq 
transactivates the meq promoter but represses the bidirectional pp14/38 promoter. 
Because Meq has been shown to bind the MDV Ori, it is possible that Meq homodimers 
repress the pp38/14 promoter by binding this sequence element. In addition to regulating 
pp38 expression, an MDV protein highly expressed during lytic infection, Meq was also 
shown to bind the ICP4 promoter by ChIP analyses. Therefore Meq may also potentially 
regulate the expression of an additional lytic protein ICP4 (42, 61). This, together with 
luciferase reporter data, suggests that Meq heterodimers activate AP-1 containing 
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promoters, therefore potentially activating genes associated with cell proliferation, while 
Meq homodimers may repress genes associated with lytic infection and consequently 
may be involved in regulating lytic or latent infection.  Collectively, these data point to a 
role of Meq heterodimers in transformation and Meq homodimers in regulation of viral 
replication. In order to delineate the functions of Meq and address the role of Meq 
homodimers in MDV pathogenesis, a recombinant Meq mutant virus (rMd5-MeqGCN) 
expressing a chimeric meq gene (MeqGCN) was constructed by substituting the parental 
Meq leucine zipper with that of the leucine zipper of the yeast protein GCN4. The 
leucine zipper region of GCN4 allows for the formation of only homodimers (37), thus 
conferring homodimerization of MeqGCN. The homodimerization and DNA binding 
and transactivation/repression properties of MeqGCN were tested in vitro. Recombinant 
virus expressing MeqGCN was studied in vitro and in vivo and compared to parental 
rMd5 and rMd5∆Meq viruses. In vitro rMd5-MeqGCN replicated similarly to parental 
rMd5; however, infection of chickens with rMd5-MeqGCN did not result in tumor 
formation. We therefore present the first in vivo evidence that Meq homodimers are not 
sufficient in MDV transformation. Our data also showed that subtle mutations of Meq 
are effective in generating a non-virulent recombinant MDV, paving the way to the 
development of improved recombinant vaccine based on Meq mutations. 
 
Materials and methods 
 
Cells and viruses  
Primary duck embryonic fibroblasts (DEF) were used for virus propagation, virus 
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reactivation assay, growth curves and DNA transfections. Recombinant viruses were 
generated from cosmids derived from a very virulent MDV strain, Md5 (64). The 
previously described rMd5ΔMeq was also used in this study (50). Chicken embryonic 
fibroblasts (CEF) were inoculated with rMd5-MeqGCN virus to obtain viral DNA used 
for transfection to recover a revertant virus (rMd5-MeqGCNR). The DF-1 cell line was 
used for luciferase assays and co-immunopreciptation (Co-IP) experiments (35). DEF 
and CEF were maintained in Leibowitz-McCoy (LM) media supplemented with 5% 
bovine calf serum (BCS) and penicillin-streptomycin at 37°C. The DF-1 cell line was 
maintained in LM media supplemented with 4% fetal bovine serum (FBS) and 
penicillin-streptomycin at 37°C. 
 
Cosmids  
Previously described cosmids SN5, P89, SN16, A6 and B40, encompassing the 
entire genome of the very virulent strain Md5 (64) were used to generate a recombinant 
Md5 (rMd5) virus and a recombinant Md5 with a chimeric Meq gene containing the 
leucine zipper from GCN4 (Fig. 1, 2).  
To generate mutations in the meq gene, a 741 bp DNA fragment referred to from 
here forward as meq-KpnI, which contains the coding sequence for meq nucleotides 1- 
385 was mutated by a series of subcloning steps and overlapping PCR.  The meq-KpnI 
fragment is located within the EcoQ fragment of the Md5 genome (Fig. 1).  
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Fig. 1. Cosmid clones used to recover recombinant viruses. (A) Organization of the 
serotype 1 MDV genome. (B) Schematic representation of the overlapping cosmid 
clones used to reconstitute recombinant viruses, rMd5 and rMeqGCN, derived from a 
very virulent (vv) strain of MDV (Md5). (C) Location of EcoQ fragment and Meq gene 
in cosmids SN5 and A6. (D) Location of Kpn1 site described in materials and methods, 
located within the EcoQ fragment at nucleotide 385 of the meq gene.  
 
First, the EcoQ fragment was released from previously described cosmids A6 
and SN5 using recA assisted restriction endonuclease (RARE) method (22). Briefly, 
recA and primers SR1116 (5’- GAA TCG GAT TTG GAA TAA CCG AAT TCG GTG 
ATA TAA AGA C -3’) and SR1117 (5’- GAC ATT ACA AGA ATA GTT TGA ATT 
CTC GGG ATA ATC TCC C -3’) were used to protect the flanking EcoRI sites of the 
EcoQ fragment during the EcoRI methylation reaction. The unmethylated EcoRI sites 
were digested with EcoRI releasing. the EcoQ fragment, which was subsequently cloned 
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into pCR2.1 (Invitrogen, Carlsbad, CA). The digested A6 and SN5 cosmids were self-
ligated generating A6∆EcoQ and SN5∆EcoQ and HB101 competent bacteria transduced 
using Gigapack III (Stratagene, La Jolla, CA) according to manufacturer’s 
recommendations. Next, the meq-KpnI fragment was released from pCR2.1-EcoQ by 
digestion with KpnI, and the fragment gel purified, using the QIAEX II Gel Extraction 
Kit (Qiagen, Valencia, CA) and cloned into KpnI digested pCR2.1 vector. Overlapping 
PCR, in a combination of three PCR reactions, was performed to replace the leucine 
zipper region of meq with the leucine zipper region of GCN4. Two primary PCR 
reactions were performed to generate the 5’ and 3’ ends of meq-KpnI fragment. The 5’ 
reaction was performed using primers M13R (5’- CAG GAA ACA GCT ATG AC -3’) 
and SR1192-GCN4 Leucine Zipper Reverse (5’- CTC ATT TTC CAA GTG ATA ATT 
TTT CGA AAG CAA TTC TTC AAC CTT GTC TTC AAG TTT GTC TAC ATA GTC 
CGT CTG CTT CCT -3’).  The 3’ end PCR reaction was performed using primers 
SR1190 (5’- GAC CGA GAT AGG GTT GAG TG -3’) and SR1193-GCN4 Leucine 
Zipper Forward (5’- AAA AAT TAT CAC TTG GAA AAT GAG GTT GCC AGA 
TTA AAG AAA TTA GTT GGC GAA CGC CGT GTA CAG TTG GCT TGT CAT 
GAG CCA -3’). Both amplicons were gel purified, mixed together and used as templates 
in a third PCR reaction with primers M13R and SR1190, generating a full meq-KpnI 
fragment containing the GCN4 leucine zipper in place of the meq leucine zipper (meq-
GCN4-KpnI). The meq-GCN4-KpnI fragment was subsequently cloned into pCRBlunt 
(Invitrogen) transformed into E.coli Top10 cells and positive clones were identified by 
restriction digestion and fully sequenced. The meq-GCN4-KpnI fragment was then 
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released by KpnI digestion and cloned into pcr2.1-EcoQ∆KpnI, replacing the parental 
meq-KpnI fragment contained in this region. The newly generated EcoQ fragment 
(EcoQ-MeqGCN) containing the mutated meq leucine zipper (MeqGCN) was then 
transferred into cosmids A6∆EcoQ and SN5∆EcoQ using RARE. The EcoRI site of 
cosmids A6∆EcoQ and SN5∆EcoQ was protected during the methylation reaction using 
recA and primer SR1130 (5’- GAA TCG GAT TTG GAA TAA CCG AAT TCT CGG 
GAT AAT CTC CCG ATG G -3’) then subjected to EcoRI restriction digestion to 
linearize the cosmids and subsequently ligated to the EcoQ-MeqGCN fragment yielding 
cosmids SN5-MeqGCN and A6-MeqGCN. Following ligation and transduction, clones 
containing the Eco-MeqGCN fragment in the correct orientation were identified by PCR 
and selected positive colonies sequenced across the junction regions.  The integrity of 
the SN5-MeqGCN and A6-MeqGCN cosmids was confirmed by evaluating their 
restriction digestion pattern. 
 
Transfections  
Parental and mutant cosmids DNA were digested with NotI, to release the viral 
insert, and purified by phenol chloroform extraction and ethanol precipitation before 
transfection. To generate rMd5 and rMd5-MeqGCN, 500 ng of cosmids P89, SN16, 
B40, SN5 and A6 or P89, SN16, B40, SN5-MeqGCN and A6-MeqGCN, respectively, 
were used to transfect 1.2 X 106 DEF in 60 mm dishes by the calcium phosphate 
procedure. Five days after transfection, cells were trypsinized and seeded onto a 100 mm 
dish and monitored for cytopathic effects. Viral stocks of recovered viruses were 
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subsequently made in DEF for further analysis. 
 
Revertant virus 
To generate a revertant virus containing the parental meq gene, gel purified 
parental Md5 EcoQ fragment together with proteinase K digested and phenol-
chloroform extracted rMd5-MeqGCN genomic DNA, were used to co-transfect CEF by 
the calcium phosphate procedure. After viral plaques were evident, the cells were 
overlayed with 0.9 % bactoagar in growth media and individual plaques harvested by 
trypsinization. Cells from each plaque were divided into two aliquots: one was used to 
infect DEF and the other for DNA extraction and PCR analysis. Presence of parental 
meq or GCN4 leucine zipper sequences in individual plaques were detected by PCR 
using the following primers: SR1118-meq start primer (5’- GAT CCC GGG GAG ATG 
TCT CAG GAG CCA GAG C -3’) and leucine zipper specific reverse primers SR3073-
meq leucine zipper (5’- GTC CTT AGA TCT CGA ATT TCC -3’) or SR3074-GCN4 
leucine zipper (5’- CTA ATT TCT TTA ATC TGG CAA C -3’), for parental and GCN4, 
respectively.  
 
Indirect immunofluorescence assay (IFA) and immunohistochemistry (IHC) 
Confluent DEF monolayers were infected with rMd5 or rMd5-MeqGCN, and 
when viral plaques were apparent, cells were fixed with ice-cold acetone/alcohol (6:4) 
and expression of Meq evaluated by IFA using rabbit polyclonal anti-Meq antibodies 
(1:300). Lymphocytes collected for reactivation assays were deposited on a microscope 
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slide using a cytospin centrifuge, fixed with ice-cold acetone/alcohol (6:4) and 
expression of pp38 evaluated by IFA using the H19 pp38 specific monoclonal antibody 
(1:400). For IHC, lymphoid organs (thymus, spleen and bursa of Fabricius), and feather 
follicles from infected and uninfected chickens were embedded in optimal cutting 
temperature compound (Tissue-Tek, OCT, Sakura Finetek, Torrance, CA), immediately 
frozen in liquid nitrogen and stored at -80°C until use. Six- to 8-µm-thick cryostat 
sections of tissue were prepared and fixed with cold acetone at -20°C for 5 min, and air-
dried. Immunostaining was carried out using H19 pp38 monoclonal antibody (1:3000) 
and the Vectastain ABC kit (Vector Laboratories, Burlingame, CA) according to the 
manufacturer’s instructions. 
 
MeqGCN homodimerization  
For in vitro homodimerization assays, parental meq and MeqGCN were cloned 
into the pcDNA3.1 (Invitrogen) eukaryotic expression vector. Both meq and MeqGCN 
genes were cloned in frame with HA and Flag tags to aid in protein detection (31). The 
resulting plasmids were denoted as pHA-MeqGCN, pFlag-MeqGCN, pHA-Meq, and 
pFlag-Meq.   
DF-1 cells were cotransfected with 2 µg of either pFlag-Meq or pFlag-MeqGCN 
and 2 µg of pHA-Meq-, pHA-MeqGCN, pCMV-cJun or pRCAS-cFos using Fugene 6 
(Roche, Mannheim, Germany).  Both pCMV-cJun and pRCAS-cFos are generous gift 
from Dr. Junnlin Liu, M. D. Anderson).  Cells were harvested 48 hours after transfection 
and lysed in RIPA buffer (10 mM Tris-HCl [pH 7.4], 1% NP-40, 0.1% sodium 
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deoxycholate, 150mM NaCl, 1mM EDTA, 1mM PMSF).  Cell lysates (500 µl) were 
immunoprecipitated with 20 µl of Flag antibody-conjugated agarose beads (Sigma, St. 
Louis, MO). Meq/c-Jun or Meq/c-Fos heterodimer were immunoprecipitated with 3 µg 
of either anti-cFos antibody (Santa Cruz, Santa Cruz, CA) or anti-cJun antibody (Santa 
Cruz) for two hours. The immune complex was then captured by the addition 20 µl of a 
protein A and protein G sepharose bead mixture and rocked for an additional 2 h at 4°C. 
Beads were washed four times with RIPA buffer and boiled for 5 min in 20 µl of 2 X 
sodium dodecyl sulfate (SDS) sample buffer (125 mM Tris-HCl [pH 6.8], 4% SDS, 10% 
2-mercaptoethanol, 20% glycerol, 0.6% bromphenol blue) and subjected to SDS-PAGE 
electrophoresis and transferred to PVDF membranes. After blocking for 1 h at room 
temperature (RT) with 5 % skim milk in TBST (20 mM Tris-HCl [pH 7.5], 137 mM 
NaCl, 0.05% Tween 20), the membranes were incubated with primary antibodies for 2 h 
at RT. The membranes were washed with TBST three times for 10 min each at RT, and 
incubated with horseradish peroxidase-conjugated antibodies for 1 hour at RT. 
Membranes were washed three times with TBST and visualized with enhanced 
chemiluminescence reagent (Amersham-Pharmacia, Piscataway, NJ). Final dilutions of 
the primary antibodies for immunoblotting were 1:500 for anti-HA tag antibody 
(Convance, Berkley, CA), 1:4000 for anti-Meq (41), 1 µg/mL for anti-cFos (Santa Cruz, 
CA), and 1 µg/mL for anti-cJun (Santa Cruz). 
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Expression of recombinant Meq and MeqGCN proteins 
Recombinant parental Meq and MeqGCN proteins were produced using a 
baculovirus expression system (Invitrogen). Parental meq and meqGCN genes were 
cloned into a modified pFAST-BAC vector, which carries a Flag tag. One hundred 
million Sf9 cells were infected with recombinant baculoviruses, expressing either Flag 
tagged Meq (Flag-Meq) or Flag tagged MeqGCN (Flag-MeqGCN).  Cells were 
harvested 48 hours after infection and lysed in lysis buffer (50 mM Tris-HCl [pH7.5], 
500 mM NaCl, 2% glycerol) supplemented with protease inhibitor cooktails (Roche).  
Cleared lysates were incubated overnight with 100 µl of Flag antibody-conjugated 
agarose beads followed by four washes with lysis buffer. Recombinant proteins were 
then eluted with 3x Flag peptides according to manufacture’s protocol. The purity and 
concentration of protein was measured by SDS-PAGE and Coomassie blue staining 
using BSA as a standard. 
 
Electromobility shift assay (EMSA) 
EMSA analysis was performed with baculovirus expressed recombinant purified 
Meq proteins. The DNA binding activity of Flag-Meq and Flag-MeqGCN was tested 
with two different probes, an AP-1 consensus oligo (5’- CGC TTG ATG AGT CAG 
CCG GAA -3’) (Promega, Madison, WI) and a probe derived from the MDV Ori (5’-
TGC TCA TTT GCA TAC ACA TCA CGT GAT AGT -3’). Probes were labeled at the 
5’ ends with  [32P] ATP and polynucleotide kinase following manufacturer’s instructions 
(Promega). Purified recombinant Meq, or MeqGCN proteins (160 ng) were incubated for 
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20 min at 30°C in gel shift buffer (Promega) followed by additional 20 min incubation 
with approximately 10,000 cpm labeled probe. For competition reactions, purified 
proteins were first incubated with unlabeled probes for 20 min at 30°C prior to 
incubation with labeled probes. Reaction products were resolved on nondenaturing 6% 
polyacrylamide-Tris-glycine gels and visualized using a Fuji film Bas-1800 II phosphor 
imaging system.   
 
Luciferase assays 
The transactivation/repression activity of the MeqGCN protein was evaluated on 
MDV promoters by luciferase assay. The meq promoter region (nucleotides -355 to -1) 
was cloned into the pGL3 vector (Promega) to form the pGL3-meq promoter. The pp38 
and pp14 promoters cloned into the pGL3 reporter vector and have been previously 
described (42). Three tandem copies of the MDV Ori sequence (TGC TCA TTT GCA 
TAC ACA TCA CGT GAT AGT) found within the pp38/pp14 bidirectional promoter 
were cloned into pGL2-TATA luciferase vector (a kind gift from Dr. Stephen Safe, 
Texas A&M University) to generate pGL2-3XOri. The meq and MeqGCN genes were 
cloned into the pcDNA 3.1 Zeo vector (Invitrogen) to generate expression vectors, 
pcDNA-Meq and pcDNA-MeqGCN. DF-1 cells (1 X 105) were seeded in 12-well plates 
16 hr prior to transfection and incubated at 37°C under standard conditions. 
Transfections were performed using siPORT XP-1 (Ambion, Austin, TX), 500 ng of 
pcDNA (empty vector control), pcDNA-Meq, or pcDNA-MeqGCN and either 250 ng of 
pGL3-meq promoter vector, pGL2-Ori or 500 ng of pp38 and pp14 promoter vectors, 
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according to manufacturer’s recommendations. Cell lysates were harvested 48 hours 
post-transfection with active lysis buffer (Promega) and luciferase assay performed 
using a Biotek Clarity luminometer (Biotek, Winooski, VT). The protein concentration 
in each transfected sample was measured by Bradford assay (Bio-Rad, Hercules, CA) 
and luciferase activity was normalized to protein concentration. Assays were performed 
in triplicate and three independent experiments were performed for each reporter vector 
tested. Transactivation or transrepression activity was expressed as fold difference 
relative to empty pcDNA vector control. Results of all three experiments were analyzed 
by one-way ANOVA followed by Tukey HSD test using the  SPSS®, Version 14.0 
software (SPSS Inc., Chicago, IL, USA). For all analysis, p ≤ 0.05 was considered 
statistically significant. 
 
Colony formation in soft agar 
DF-1 cells were transfected with pcDNA, pcDNA-Meq or pcDNA-MeqGCN 
using siPORT XP-1 (Ambion). Approximately 48 hours after transfection the transfected 
DF-1 cells were selected with 300 µg/ml zeocin (Invitrogen) for 4 weeks. Expression of 
Meq was confirmed by IFA using Meq antibody as described above. Pools of resistant 
cells (5 X 103) were seeded in 0.33% agarose containing LM media with 150 µg/ml 
zeocin and 10% FBS overlaid on a 0.5% agarose in a 35-mm plate. After 3 weeks of 
culture colonies were examined under a light microscope and photographed using 12 X 
magnification. Three different fields were randomly selected and colonies greater than 
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100 µm were counted. Two independent experiments were performed and each 
experiment was performed in triplicate. 
 
Southern blot 
DNA from rMd5, rMd5-MeqGCN and rMd5∆Meq infected DEF was isolated by 
proteinase K digestion followed by phenol-chloroform extraction and ethanol 
precipitation. Three micrograms of each DNA sample was digested with either EcoRI or 
PstI, separated on a 1% agarose gel, and transferred to nylon membranes. 32P-dCTP-
labeled probes representing the complete MDV genome (cosmids SN5, P89, SN16, A6 
and B40) or EcoQ fragment (2,456-bp fragment) were generated by random priming 
using High Prime DNA Labeling Kit (Roche) and were used to hybridize to viral DNA, 
using standard protocols (68). 
 
In vitro growth kinetics  
To compare the growth characteristics of rMd5 and rMd5-MeqGCN, DEF seeded 
on 35 mm plates were inoculated with approximately 50 plaque forming units (pfu) of 
each virus. On days 2, 4 and 6 after inoculation, the infected cells were trypsinized, 
serial dilutions inoculated onto DEF monolayers, seeded on 35 mm plates, and plaques 
at the different dilutions counted 7 days later. 
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Pathogenesis experiments 
Experiment 1 
To study the effect of Meq homodimers on viral replication, 4-week-old SPF 
chickens (Hy-Vac, Adel, Iowa) were randomly sorted into experimental groups of nine 
chickens each. One group remained as a non-inoculated control, whereas the other 
groups were inoculated subcutaneously with 3,000 pfu of rMd5, rMd5-MeqGCN or 
rMd5∆Meq. Three chickens were randomly selected at each time point, except at day 6 
in which two chickens were selected. On 14 and 21 dpi blood samples were collected in 
heparin, for reactivation assays (see below), and were subsequently euthanized for tissue 
sample collection. On 6 and 21 dpi lymphoid organs and feather follicles were collected 
for IHC. On 14 dpi, lymphoid organs were collected to determine lymphoid organ/body 
weight ratios. Organ/body weight ratios between groups were analyzed using the 
Kruskal-Wallis test with significance set at p<0.05.  
 
Experiment 2 
To study the role of the Meq homodimers on oncogenesis, SPF (Hy-Vac) day old 
chicks (nine per group) were inoculated subcutaneously with 2,000 pfu of one of the 
following viruses: rMd5, rMd5-MeqGCN or rMd5∆Meq and reared in modified 
Horsfall-Brauer isolation units for 8 weeks. Weekly mortality was recorded and all 
chickens were necropsied at time of death or at termination of the experiments and 
evaluated for MDV-specific lesions in the viscera and the nerves. To confirm that the 
phenotypic changes observed in rMd5-MeqGCN were due to the exclusive 
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homodimerization of Meq, a revertant virus (rMd5-MeqGCNR) was inoculated into 
three chickens (3,000 pfu) and evaluated for MDV specific lesions.  
 
Experiment 3 
To study the role of Meq homodimers on horizontal transmission, six SPF 
(Charles River) day old chicks were inoculated subcutaneously with 3,000 pfu with 
rMd5 or rMd5-MeqGCN, three additional uninoculated chicks were reared with each 
group and served as contacts to assess horizontal transmission. At 8 weeks post-infection 
(PI) buffy coats were obtained from heparinized blood by centrifugation at 500 X g. 
DNA was extracted using Purelink Genomic DNA extraction kit (Invitrogen) and PCR 
was performed using MDV specific Meq primers SR1118 (5’-GAT CCC GGG GAG 
ATG TCT CAG GAG CCA GAG C-3’) and SR1135 (5’-GAT CCC GGG TCA GGG 
TCT CCC GTC ACC TGG AAA CC -3’) to detect the presence of MDV genome.  
 
Reactivation assay 
Buffy coats were collected as described above at 14 and 21 dpi. DEF monolayers 
seeded in 35 mm plates, were inoculated with 106 lymphocytes in duplicate and viral 
plaques counted 7 days post inoculation. 
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Results  
 
Mutations in the leucine zipper of Meq are sufficient to confer homodimerization 
It has previously been shown that Meq has the ability to form homodimers and 
heterodimers like the Jun family of bZIP transcription factors with which Meq shares 
considerable homology (42). It is well established that the specific amino acid residues 
within the leucine zipper of bZIP proteins determine their dimerization properties. 
Among these transcription factors, the yeast protein GCN4 is well characterized and the 
leucine zipper region is known to allow for the exclusive formation of homodimers (37). 
Like other studies (27, 29, 34), we also utilized the leucine zipper region of GCN4 in 
place of the parental leucine zipper of Meq, to study the function of Meq homodimers in 
MDV pathogenesis.  The leucine zipper of Meq was successfully “swapped” with the 
leucine zipper of GCN4 using overlapping PCR, resulting in a Meq homodimer mutant, 
MeqGCN (Fig. 2). 
 
 
Fig. 2. Schematic representation of the meq and GCN4 leucine zippers (LZ). The DNA 
binding basic regions (BR1 and BR2) and transactivation domains, are depicted. The LZ 
sequence of parental meq and GCN4 used to replace parental meq LZ in rMd5-MeqGCN 
are shown. Asterisks indicate the conserved leucine sites. 
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The open reading frames of Meq and MeqGCN, fused to the FLAG and HA 
epitope tags (HA-Meq, Flag-Meq, HA-MeqGCN, Flag-MeqGCN) were expressed in 
DF-1 cells. Co-immunoprecipitation experiments were performed with anti-Flag 
antibody-conjugated beads to test if the leucine zipper mutations in MeqGCN were 
sufficient to confer homodimerization (Fig. 3). First, Flag-Meq or Flag-MeqGCN was 
co-transfected with HA-Meq in DF-1 cells (Fig. 3a, left panel). Flag-Meq protein 
complexes were immunoprecipitated with anti-Flag antibody and evaluated for the 
presence of HA-proteins by Western blot analysis. Flag-Meq, but not Flag-MeqGCN 
effectively precipitated HA-Meq. Conversely, Flag-MeqGCN precipitated HA-MeqGCN 
but not HA-Meq (Fig. 3a right panel).   These results demonstrated the strong 
homodimerization property of MeqGCN.  
As a next step, the ability of Meq and MeqGCN to dimerize with c-Jun or c-Fos 
was examined (Fig. 3b). Meq or MeqGCN were co-expressed with c-Fos or c-Jun, and 
their ability to heterodimerize with other bZIP family protein assessed. As shown in the 
left panel of Fig. 3b, while Meq effectively pulled down c-Fos, very little, if any, c-Fos 
was found to associate with MeqGCN. Likewise, c-Jun interacts with Meq much more 
avidly than MeqGCN. This and the above experiment suggest MeqGCN preferentially if 
not exclusively, forms homodimer under physiological conditions. 
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Fig. 3. Homo- and hetero-dimerization of Meq and MeqGCN proteins (a) Co-
immunoprecipitation analysis of tagged Meq and MeqGCN proteins. Indicated plasmids 
were cotransfected in DF-1 cells. Twenty percent of total cell lysates that were used for 
coimmunoprecipitation were also included as controls.  Meq coprecipitates only with 
Meq (left panel), and MeqGCN coprecipitates only with MeqGCN (right panel), 
demonstrating homodimerization. Membranes were reprobed with anti-Flag antibody as 
a control (b) MeqGCN had impaired ability to form heterodimer with c-Jun or c-Fos. 
The indicated plasmids were cotransfected in DF-1 cells, and immunoprecipitated with 
either anti-Fos or anti-Jun antibody, and blotted with anti-Meq antibody. Ten percent of 
total cell lysates that were used for immunoprecipitation were also included in the same 
gel as a control. Both c-Fos and c-Jun are effectively precipitated Meq but only weakly 
precipitate MeqGCN.  
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Meq homodimer mutant (MeqGCN) retains DNA binding, transactivation and repressive 
functions 
Previous characterization of Meq has shown that Meq homodimers and 
heterodimers differ in their DNA binding affinities. Although both Meq homodimers and 
heterodimers bind AP-1 sequences, Meq together with c-Jun bound AP-1 sequences with 
greater affinity than Meq alone.  In addition, Meq alone bound the MDV origin of 
replication (MDV Ori) located in the pp38/14 bidirectional promoter (42). Luciferase 
reporter assays indicated functional differences between Meq and Meq plus c-Jun in that 
although Meq activated the AP-1 containing meq promoter, Meq plus c-Jun resulted in 
higher activation. Furthermore, Meq expression was shown to repress the MDV 
pp38/pp14 bidirectional promoter which contains the MDV Ori (42). Therefore, EMSA 
and luciferase assays were performed to test if the DNA binding and 
transactivation/repression functions of MeqGCN were still functional. Recombinant 
Flag-Meq Flag-Meq and Flag-MeqGCN proteins were prepared from recombinant 
baculovirus infected cells. Recombinant proteins were incubated with 32P labeled 
consensus AP-1 oligo or an oligo encompassing a portion of the MDV Ori. Both Meq 
and MeqGCN proteins bound both AP-1 and MDV Ori oligos and the intensity of band 
shifts for both Meq and MeqGCN decreased in the presence of specific competitor, 
indicating specific binding (Fig. 4).  
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Fig. 4. Electromobility shift assay (EMSA) analyses of Meq and MeqGCN proteins were 
preformed to test the DNA binding capacity of MeqGCN. Purified baculovirus 
expressed proteins, Meq and MeqGCN, were incubated with radiolabeled 
oligonucleotide probes followed by gel retardation analysis. Two different probes were 
used: a consensus AP-1 oligo and ACACA probe derived from the MDV origin of 
replication (MDV Ori). Band shifts are observed by Meq and MeqGCN (black arrow), of 
which the intensity decreases in the presence of unlabeled competitor. NS, non-specific 
bands. 
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Luciferase assays were then performed to test the transactivation and repressive 
functions of MeqGCN compared to Meq. DF-1 cells were transfected with pcDNA 
empty vector, pcDNA-Meq or pcDNA-MeqGCN, together with pGL3- meq promoter 
reporter vector.  As shown in figure 5, both Meq and MeqGCN activated the meq 
promoter, although MeqGCN activated the meq promoter to significantly lesser levels 
than Meq (p<0.05).  Luciferase assays were also performed to test the ability of 
MeqGCN to repress the previously described pp38 and pp14 promoters. DF-1 cells were 
transfected with pcDNA, pcDNA-Meq, or pcDNA-MeqGCN, and either the pGL3-pp38 
or pGL3-pp14 promoter reporter vectors.  Although, pcDNA-Meq and pcDNA-
MeqGCN repressed both, pp38 and pp14 promoters, repression by pcDNA-MeqGCN 
was significantly less (p<0.05) than parental pcDNA-Meq protein (Fig. 5). Nonetheless, 
both pcDNA-Meq and pcDNA-MeqGCN significantly repressed the pGL2-3X-Ori, 
which contains three copies of the sequence element found in the pp38/14 bidirectional 
promoter that Meq was previously reported to bind (42, 61).  
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Fig. 5. Luciferase assays demonstrate that MeqGCN has functional transactivation and 
repression activities. DF-1 cells were transfected with meq-promoter, pp14 promoter, 
pp38 promoter or 3X-Ori luciferase reporter plasmids and pcDNA (empty vector), 
pcDNA-Meq or pcDNA-MeqGCN. Both Meq and MeqGCN activate the meq-promoter 
and repress the pp38/14 bidirectional promoters and 3X-Ori indicating MeqGCN 
maintains transactivation/repressive functions. Luciferase values are expressed as fold 
difference relative to pcDNA vector. Significance (*) equals p ≤ 0.05. Error bars indicate 
SD. 
 
Colony formation in soft agar 
Colony formation in soft agar is a marker of transformation and Meq expression 
in fibroblasts has been shown to promote anchorage independent growth (41). Soft agar 
 
 
 
* 
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assay was employed to test the ability of Meq homodimers to promote colony formation 
in soft agar. Meq and MeqGCN expression in selected DF-1 cells was confirmed by IFA 
(Fig. 6a top panel). As expected, selected DF-1 cells expressing the pcDNA-Meq 
construct formed large colonies in soft agar when compared to control cells selected with 
pcDNA empty vector (Fig. 6a bottom panel). Furthermore, cells expressing pcDNA-Meq 
had 23 X more colonies >100 µm in size compared to pcDNA control cells.  
 
 
Fig. 6. In vitro soft agar assay demonstrating that MeqGCN has reduced transformation 
potential. (a) Top panel: Immunofluorescence analysis of Meq expression from pools of 
selected DF-1 cells transfected with pcDNA, pcDNA-Meq, pcDNA-MeqGCN. Bottom 
panel: Soft agar assay was performed using pcDNA, pcDNA-Meq, pcDNA-MeqGCN 
selected DF-1 cells to assess anchorage independent growth. (b) Number of colonies > 
100 µm observed in cells expressing pcDNA, pcDNA-Meq, or pcDNA-MeqGCN. 
Average number of colonies counted from three random fields are shown. Error bars 
indicate SD. 
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In contrast, DF-1 cells expressing pcDNA-MeqGCN only had 3.5 X as many 
colonies >100 µm in size compared to empty vector control cells (Fig. 6b), indicating 
that Meq homodimers have a reduced potential for transformation in vitro. 
 
Construction of a Meq-homodimer mutant virus rMd5-MeqGCN 
A recombinant Md5 mutant virus in which the leucine zipper region of meq was 
replaced with the corresponding region of GCN4 (rMd5-MeqGCN) was successfully 
constructed. The leucine zipper region of the meq gene was replaced with the leucine 
zipper region of GCN4 by overlapping PCR, and the EcoQ fragment containing the 
chimeric meqGCN gene was cloned into the A6∆meq and SN5∆meq cosmids. The 
resultant cosmids A6-MeqGCN and SN5-MeqGCN together with cosmids P89, B40 and 
SN16 were cotransfected into DEF by the calcium phosphate method and a recombinant 
virus was subsequently recovered by homologous recombination. Southern blot analyses 
were performed to assess the integrity of the rMd5-MeqGCN viral genome.  Genomic 
DNA from rMd5, rMd5-MeqGCN and rMd5∆Meq infected DEF was digested with 
EcoRI or PstI and probed with 32P labeled Md5 comids or EcoQ fragment DNA, 
respectively.  No differences were observed between rMd5 and rMd5-MeqGCN EcoRI 
digestion patterns confirming the integrity of the recombinant genomes (Fig. 7). DNA 
from rMd5, rMd5-MeqGCN and rMd5∆Meq infected DEF was also digested with PstI 
because there is a PstI site located within the leucine zipper region of the meq gene 
which it is absent in the mutant MeqGCN gene. As expected, PstI digested rMd5-
MeqGCN DNA probed with 32P labeled EcoQ fragment resulted in a single band 
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compared to two bands observed for rMd5 (Fig. 7). Like rMd5-MeqGCN, rMd5∆Meq, 
also lacks the PstI site due to the deletion of the meq gene, therefore a single yet smaller 
band was detected by Southern blot (Fig. 7).  
                     
Fig. 7. Southern blot analysis of rMd5, rMd5-MeqGCN and rMd5∆Meq. (A) DNA was 
digested with EcoRI and probed with total viral MDV DNA. The restriction profile of 
rMd5-MeqGCN is similar to rMd5, indicating no gross genome rearrangements 
incurred. The arrow indicates the location of the EcoQ fragment.  Due to the meq 
deletion in the EcoQ fragment of rMd5∆Meq this fragment migrates faster. B) DNA was 
digested with PstI and probed with EcoQ fragment. The introduced LZ mutations in 
rMd5-MeqGCN resulted in a lost of a PstI site, and therefore a single band is observed, 
in contrast to two bands for rMd5. Likewise, rMd5∆Meq does not have a PstI site and as 
a consequence of the meq deletion resulting in a faster migrating single band. 
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Fig. 8. Immunofluorescence analysis of DEF cells infected with recombinant viruses. (a) 
rMd5∆Meq infected DEF (150 X), (b) rMd5-MeqGCN infected DEF (100 X) (c) rMd5 
infected DEF (100 X) (d) rMd5-MeqGCN infected DEF (1000 X). Meq expression is 
observed in the nucleus of rMd5 and rMd5-MeqGCN infected DEF but not rMd5∆Meq.  
 
Immunofluorescence assay (IFA) was performed to evaluate Meq expression in 
virus infected DEF. Meq expression was observed in both rMd5 and rMd5-MeqGCN 
infected DEF but not in rMd5∆Meq infected cells. In addition, magnification at 1000 X 
clearly showed that expression of MeqGCN localized to the nucleus (Fig. 8). While, less 
expression was observed in rMd5-MeqGCN compared to rMd5, this correlates with 
luciferase data, which indicated that MeqGCN activated the meq promoter to a lesser 
extent than parental Meq (Fig. 5).  
 
In vitro and in vivo replication of rMd5-MeqGCN 
The in vitro growth properties of rMd5-MeqGCN were tested, to assess if the 
leucine zipper mutations had any effect on virus replication in vitro. Our results indicate 
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that rMd5 and rMd5-MeqGCN virus replicated similarly at the time points tested (days 
0, 2, 4, 6) (Fig. 9).   
 
                        
Fig. 9. In vitro growth properties of rMd5 and rMd5-MeqGCN. DEFs were infected with 
the indicated viruses, harvested on days 2, 4 and 6 after infection and titered on fresh 
DEF. Day 0 indicates the titer of the virus in the inoculum. The experiment was 
performed in duplicate, and the titer (logarithm of the mean number of plaque-forming 
units per dish) is indicated. 
 
To test the role of Meq homodimers in in vivo replication, 4-week-old SPF 
chickens were inoculated with 3,000 pfu of rMd5, rMd5-MeqGCN or rMd5∆Meq virus. 
Six days after inoculation two randomly selected birds were euthanized and lymphoid 
organs (thymus, spleen and bursa of Fabricius) collected and evaluated for viral lytic 
antigen (pp38) expression by IHC. Expression of pp38 was evident in bursa of Fabricius 
(Fig. 10) thymus and spleen (data not shown) of both rMd5 and rMd5-MeqGCN infected 
chickens, indicating that the leucine zipper mutations in the rMd5-MeqGCN virus did 
not affect early cytolytic infection.  
 50 
 
 
Fig. 10. Infection of lymphoid tissue and feather follicles. Immunohistochemistry of 
bursa and feather follicle 6 and 21 dpi, respectively with anti-pp38 monoclonal antibody 
(H19). Positive cells are indicated by brown precipitate, counterstaining was performed 
with hematoxylin.  
 
To further assess the role of Meq homodimers in viral replication, lymphoid 
organ weight ratios were determined, from three birds from each group at day 14 PI, to 
evaluate lymphoid organ atrophy. As expected, splenomegaly as well as thymic and 
bursal atrophy was observed in chickens inoculated with rMd5, indicating high levels of 
cytolytic infection. Although, there were no significant differences between all groups, 
bursal and thymic atrophy were less evident in the rMd5-MeqGCN group compared to 
rMd5 (Fig. 11).  
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Fig. 11. Lymphoid organ/body weight ratios of rMd5, rMd5-MeqGCN, and rMd5∆Meq 
infected chickens 14 dpi. Three birds from each group were euthanized, lymphoid 
organs collected and chickens and lymphoid organs weighed. Statistical analysis was 
performed using the Kruskal-Wallis test. Significance was set at p<0.05. Although, no 
significant differences were observed, less lymphoid organ atrophy was observed in 
chickens infected with rMd5-MeqGCN compared to rMd5.  
 
It is well documented that MDV switches from an active cytolytic infection to a 
latent infection approximately 7-8 days PI and virus reactivation can be observed when 
latently infected lymphocytes are co-cultured with fibroblasts (11).  To examine if Meq 
homodimers are involved in the establishment of latency and reactivation, peripheral 
blood lymphocytes (buffy coats) were obtained from three chickens from each group on 
days 14 and 21 PI and co-cultured with DEF.  To confirm viral infection, portions of 
collected lymphocytes were fixed on microscope slides and IFA performed to detect 
viral antigen, pp38. As shown in Table 1, few or no plaques were obtained from PBMCs 
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of chickens infected with rMd5-MeqGCN and rMd5∆Meq. Yet, at day 21, latently 
infected lymphocytes were positive for viral antigen pp38 (Fig. 12) suggesting that these 
viruses are defective in reactivation.  
 
Table 1.    
Virus reactivation from peripheral blood lymphocytes 
Group Day 14 Day 21   
rMd5 45 120  
rMd5-MeqGCN 1 0  
rMd5∆Meq 2.5 0   
 
 
Reactivation assays were performed on days 14 and 21 after inoculation. The numbers 
represent the average number of pfu observed when106 peripheral blood lymphocytes 
were co-cultured with DEF 
 
 
 
 
 
 
 
Fig. 12. Detection of MDV pp38 protein in latently infected cells 21 dpi. 
Immunofluorescence assay was performed with anti-pp38 monoclonal antibody (H19) 
on PBMC’s collected from rMd5 and rMd5-MeqGCN infected chickens. Texas-red 
conjugated secondary antibodies were used to detect pp38 and nuclei were stained with 
DAPI. 
rMd5 rMd5-GCN 
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Transmission of MDV occurs through replication of virus in the feather follicle 
epithelium (FFE) and release of dander containing infectious virus (13). Therefore, to 
determine if the rMd5-MeqGCN homodimer mutant was able to replicate in the FFE, 
expression of the lytic viral antigen pp38 was evaluated in three chickens from each 
inoculated group by IHC. Tissues from all inoculated groups tested positive for pp38 
antigen indicating the ability of rMd5-MeqGCN, like rMd5, to replicate in the FFE (Fig. 
10). To further assess the role of Meq homodimers in MDV transmission, day old SPF 
chickens were inoculated with 3,000 pfu of rMd5 or rMd5-MeqGCN and reared with 
three uninfected contact chicks. Buffy coats were collected from contact birds 8-weeks 
PI, DNA extracted and PCR for Meq performed. In both groups two out of three contact 
chickens tested positive for Meq or MeqGCN, respectively. Altogether these results 
confirm that rMd5-MeqGCN retains the ability to transmit horizontally by shedding 
through the feather follicle epithelium. 
 
Oncogenecity of rMd5-MeqGCN 
To determine if Meq homodimers are involved in transformation of T-cells, 
groups of nine SPF chickens were inoculated at day of age with 2,000 pfu of rMd5, 
rMd5-MeqGCN, or rMd5∆Meq and observed for mortality for a period of 8 weeks. All 
chickens that died during the experiment or were euthanized at the termination of the 
experiment were evaluated for MDV-specific lesions. MDV-associated mortality was 
observed in rMd5-infected chickens starting at week 4 PI and none of the chickens 
survived the end of the experiment. In contrast, all of the rMd5-MeqGCN infected 
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chickens survived the 8-week experiment and microscopic examination of the vagus, 
brachial, and sciatic nerves showed no signs of Marek’s disease. Similarly, as expected, 
the rMd5∆Meq infected chickens also survived the duration of the experiment and were 
free of MDV specific lesions (Fig. 13 and Table 2).  
                   
 
Fig. 13. Mortality in chickens inoculated with rMd5, rMd5-MeqGCN, and rMd5∆Meq. 
Chickens were inoculated with 2,000 pfu of the indicated viruses at 1 day of age, 
maintained in isolation for 8 weeks and weekly mortality was recorded. Uninoculated 
chickens served as negative controls. Chickens that died during the experiment were 
evaluated for MDV-specific gross lesions. 
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Table 2.     
Pathogenicity of rMd5, rMd5-MeqGCN, rMd5ΔMeq, and rMd5-MeqGCNR  
in SPF MDV maternal antibody-negative chickens 
   
Virusa Mortality (%)   Tumor Incidence (%)
b    
rMd5 9/9 (100)  9/9 (100)  
rMd5-MeqGCN   0/9 (0)   0/9 (0)  
rMd5ΔMeq 0/9 (0)    0/9 (0)  
rMd5-MeqGCNRc  3/3 (100)    3/3 (100)  
None  0/9 (0)   0/9 (0)   
aAll chickens were inoculated with 3,000 PFU of the indicated viruses. 
bChickens that were not positive for gross tumors were further evaluated for 
microscopic tumors 
c Performed as an independent experiment 
 
Construction and biological properties of revertant virus rMd5-MeqGCNR 
To verify that the phenotypic changes observed with rMd5-MeqGCN were due to 
changes introduced in the leucine zipper region, a revertant virus was constructed. DNA 
obtained from rMd5-MeqGCN infected CEF was co-transfected with purified parental 
MDV EcoQ DNA, which contains the meq gene. A revertant virus, rMd5-MeqGCNR, 
was selected by plaque purification, and screened for the presence of both parental and 
MeqGCN-mutant meq genes by PCR. PCR revealed that of the 130 plaques tested, 3 
contained, one copy of the parental meq gene restored in the viral genome. Three 
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chickens were infected with 3,000 pfu of rMd5-MeqGCNR and by week 5 PI all three 
were positive for MDV gross tumors, confirming that the attenuated phenotype of rMd5-
MeqGCN was due to the mutations introduced in the leucine zipper of Meq. In addition 
PCR analysis of virus isolated from the rMd5-MeqGCNR infected chickens revealed 
that both copies of the parental meq gene had been restored.  
 
Discussion 
MDV is a ubiquitous, highly contagious, potent oncogenic virus, which is 
controlled by vaccination to prevent economic losses otherwise caused by Marek’s 
disease. Due to widespread use of vaccines, MDV continues to evolve towards greater 
virulence and therefore, a better understanding of the molecular mechanisms of viral 
pathogenesis is warranted to control this economically important disease of poultry. 
A number of genes unique to MDV are encoded within the repeat long region or 
at its junction with the unique long region, and have been associated with pathogenesis. 
For example, disruption of pp38, vIL8, or LORF11 genes from oncogenic MDV resulted 
in reduced tumor incidence as a consequence of impaired lytic replication in chickens 
(17, 25, 40, 57). On the other hand, disruption of vTR (viral telomerase RNA) or meq 
gene did not appear to have an affect on lytic replication in vivo, but resulted in 60 and 
100% reduction of tumor incidence, respectively (50, 79). 
MDV-1 (GaHV-2) encoded Meq protein is consistently detected in MDV 
induced tumors and is a potentially multifaceted transcription factor which has been 
shown to directly interact with cell cycle regulator, cyclin-dependent kinase 2 (CDK2) 
and the co-repressor C-terminal-Binding Protein (CtBP) (49). Interestingly, abrogation 
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of the interaction of Meq with CtBP in an MDV-1 recombinant virus (pRB1B-Ct20) 
resulted in loss of transformation; however, the molecular mechanisms associated with 
this phenotype remain to be elucidated (8), although it can be speculated that Meq may 
interfere with the ability of CtBP to function as a co-repressor as has been described for 
adenovirus early region 1A (AdE1A) (65).  
Meq shares homology with the Jun/Fos bZIP family of transcription factors, of 
which viral counterparts v-Jun and v-Fos are oncogenic, therefore implying a similar 
oncogenic potential (73). In vitro transformation studies and the loss of transformation 
observed in vivo with rMd5∆Meq provides convincing proof that Meq is essential for 
transformation by MDV. However, the mechanisms of Meq transformation remain 
unknown. In vitro characterization of Meq DNA binding and transactivation/repression 
activities, have provided support for the hypothesis that Meq homodimers and 
heterodimers have distinct roles in MDV-1 pathogenesis (33, 41, 42, 61); however, the 
role of Meq homodimers and heterodimers in MDV-1 pathogenesis has not been 
characterized. 
In this study, a recombinant virus in which the leucine zipper of the Meq protein 
was replaced with the leucine zipper of the yeast GCN4 protein was successfully 
generated. It has been well established that the leucine zipper region of bZIP proteins 
determines their dimerization specificity, which in turn affects their DNA binding 
properties (37, 84). The mutant Meq protein we generated containing the dimerization 
domain of GCN4 retained both DNA binding and transactivation/repression functions in 
vitro. However, rMd5-MeqGCN expressed MeqGCN to a lesser extent than parental 
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rMd5 virus expressed Meq in infected DEF (Fig. 8). This correlates with in vitro 
luciferase data, which showed that parental Meq activates the meq promoter at 
significantly greater levels than MeqGCN (Fig. 5), supporting a previous report that 
Meq, together with c-Jun, has a greater binding affinity for AP-1 sequences and higher 
transactivation activity on the meq promoter than Meq alone (42). Since MeqGCN 
transactivates the Meq promoter to a lesser extent than parental Meq, it is possible that 
MeqGCN may also have decreased transactivation of other AP-1 containing promoters. 
This decrease in transactivation potential could contribute to the decreased 
transformation observed by MeqGCN in the soft agar assay (Fig. 6). However, 
transactivation activity does not always correlate with transformation as has been 
observed in studies with v-Jun mutants that are strong transactivators and poor 
transformers and vice versa. (27). We also found that MeqGCN homodimers had a 
reduced ability to transrepress the pp38/14 promoter although MeqGCN repressed 
MDVOri sequences found within the pp38/14 promoter at levels comparable to parental 
Meq. It is possible that MeqGCN homodimers in the context of the full pp38/14 
promoter are not able to bind the pp38/14 promoter as well as parental Meq or bind other 
elements in the promoter with different affinity therefore decreasing transrepression. It 
has been shown that v-Jun-GCN4 leucine zipper chimeric proteins are more stable than 
parental v-Jun homodimers and it is therefore possible that the stability of MeqGCN 
homodimers be different than that of parental Meq homodimers.  
The contribution of other MDV proteins or cellular factors to MDV 
transformation cannot be dismissed either. Disruption of Meq contact with CtBP resulted 
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in a loss of oncogenicity showing the importance of Meq and CtPB interactions (8). In 
addition, Meq has been shown to associate with cell cycle regulators, CDK2 and p53 
(38, 49), although, the contribution of these interactions in MDV transformation have 
not been defined. It remains possible that MeqGCN homodimers have altered 
interactions with these or other unknown cellular factors.  However, taken together, our 
data demonstrate that MeqGCN homodimers are not sufficient to induce transformation 
of T-cells in chickens.  Further investigations with Meq-heterodimer mutants, might aid 
in further defining the role of Meq in MDV transformation. 
The role of Meq homodimers in MDV-1 pathogenesis was determined by 
evaluating both cytolytic infection and transformation in vivo. In vitro, rMd5-MeqGCN 
replicated similar to parental virus and in vivo, cytolytic infection was evident in 
lymphoid organs and feather follicles as assessed by expression of MDV-1 lytic protein 
pp38 (Fig. 10). However, evaluation of effects of MeqGCN on cytolytic infection is 
difficult because Meq expression is not essential for early cytolytic infection (50). Meq 
is not always detected early in infection and expression of Meq in vivo, is variable and 
has been shown to depend on the virus strain and chicken line used (24, 56). As the FFE 
is the site of fully productive infection and source of horizontal transmission (13), we 
evaluated the role of Meq homodimers on transmission by IHC (Fig. 10) and contact 
transmission. Our results show that Meq homodimerization did not interfere with either 
replication in the FFE or transmission to contact chickens. 
Atrophy of thymus and bursa of Fabricius and splenomegaly is a marker of 
MDV-1 lytic infection and is a good indicator of the virulence of MDV-1 pathotypes. 
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Atrophy is evident as early as 8 days post infection with no significant differences 
observed among MDV-1 pathotypes. However, at day 14 PI, although lymphoid organ 
atrophy is less than at day 8 PI, significant differences between MDV-1 pathotypes are 
evident. By day 14 PI less atrophy is observed with less virulent pathotypes indicating 
the affected tissues are able to recover. On the other hand, a greater degree of atrophy at 
day 14 PI is observed with the more virulent pathotypes. The greater degree of atrophy 
may be a result of prolonged cytolytic infection or an able to infect a greater number of 
cell types or if they maintain a therefore causing more damage to tissue than less virulent 
strains (14). To assess the virulence of rMd5-MeqGCN, lymphoid organ/body weight 
ratios were determined for rMd5-MeqGCN, rMd5 and rMd5ΔMeq infected chickens. As 
expected, lymphoid organ atrophy and splenomagly were observed at day 14 PI in the 
rMd5-infected group, while rMd5-MeqGCN infected chickens displayed less lymphoid 
organ atrophy and were more similar to uninfected controls (Fig. 11). Although, no 
significant differences were observed at day 14 among all groups, the statistical power of 
the time point was limited due to the small number of chickens examined and may not 
accurately reflect the biological differences between these viruses. However, these 
results suggest that rMd5-MeqGCN is less virulent than parental rMd5. 
One of the goals of this study was to dissect the Meq functions, in the hope to 
separate its transforming potentials from the in vivo replication/latency functions. A 
perhaps oversimplified model is that Meq/Jun heterodimers, like v-Jun, imparts 
transforming function, whereas Meq/Meq homodimers are involved in latency entry 
and/or reactivation. To test this model, the replicative properties of rMd5-MeqGCN 
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virus were assessed in vivo by evaluating early cytolytic infection and reactivation from 
latency. Although early cytloytic infection was not impaired (Fig. 10) the virus appeared 
to be defective in reactivation (Table 1). A switch from lytic to latent infection in MDV-
1 normally occurs approximately 7 days PI, and virus from latently infected cells can be 
reactivated when co-cultured with fibroblasts in vitro (11). In our study, few viral 
plaques were detected at day 14 and none at day 21 for both rMd5-MeqGCN and 
rMd5∆Meq groups. However, although not quantitative, the presence of latently infected 
cells in the chickens was confirmed by the detection of viral antigen pp38 (Fig. 12) and 
PCR amplification of the MDV-1 genome (data not shown) in all infected groups. Since 
both rMd5-MeqGCN and rMd5∆Meq viruses appear to be defective in reactivation it 
may be argued that Meq heterodimers might play an important role in virus reactivation 
from latency.   
Inoculation of chickens with rMd5-MeqGCN also showed that this recombinant 
virus is apathogenic. During the 8-week experiment none of the chickens infected with 
rMd5-MeqGCN developed gross or microscopic tumors whereas in the rMd5 group, all 
the chickens that died or were euthanized suffered from Marek’s disease (Fig. 13). Like 
rMd5∆Meq, rMd5-MeqGCN did not transform T-cells, further supporting in vitro data 
and implicating Meq heterodimers in MDV-1 transformation. In order to rule out the 
possibility that tumor formation was inhibited by the production of antibodies directed 
towards the GCN leucine zipper, we tested convalescent chicken serum on cells 
expressing Meq and MeqGCN by IFA.  None of the sera obtained from rMd5 or rMd5-
MeqGCN infected chickens reacted positively with cells expressing either Meq or 
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MeqGCN (data not shown). These results are further supported by previous work with 
retrovirus constructs expressing v-Jun GCN4 leucine zipper mutants, which remained 
oncogenic in infected chickens (27, 34). This suggests that immune responses to 
MeqGCN did not contribute to the lack of oncogenecity observed in rMd5-MeqGCN 
infected chickens. Importantly the phenotypic differences observed in this study for 
rMd5-MeqGCN can be attributed to the leucine zipper mutations, as the Md5 phenotype 
was fully restored in the revertant virus, rMd5-MeqGCNR.  
In summary, this work provides the first in vivo evidence that Meq homodimers 
are not sufficient for MDV-1 transformation reinforcing the notion that the participation 
of Meq/Jun may be key to its transforming ability. In order to better characterize the 
Meq transcriptional pathways involved in MDV-1 pathogenesis, current studies with 
recombinant Meq heterodimer virus are underway to investigate the role of Meq-Jun 
heterodimers in MDV transformation in vivo.  
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CHAPTER III 
HETERODIMERIZATION AND HOMODIMERIZATION OF MAREK’S 
DISEASE VIRUS ENCODED MEQ PROTEIN CONTRIBUTES TO T-CELL 
TRANSFORMATION IN CHICKEN 
 
Introduction 
 Marek’s disease virus serotype 1 (MDV-1) is a potent oncogenic avian 
herpesvirus and the etiologic agent of Marek’s disease (MD). MDV elicits a rapid onset 
of malignant T-cell lymphomas within several weeks of infection, resulting in mortality. 
Although MDV shares biological characteristics with gammaherpesviruses, such as its 
ability to transform lymphocytes MDV is classified as an alphaherpesvirus, based on 
viral genome sequence and organization and is collinear with HSV and VZV (67, 74). 
Three Marek’s disease viruses have been described, MDV-1, Marek’s disease virus 
serotype 2 (MDV-2) and Meleagrid herpesvirus 1 (MeHV-1) however only MDV-1 is 
oncogenic. In addition, MDV-1 continues to evolve and a number of different 
pathotypes exist within MDV-1 ranging from mild to very virulent plus, varying in both 
cytolytic and oncogenic potential (12, 88).  
The highly oncogenic nature of MDV suggests the presence of a viral 
oncogene(s). Initial investigations in the search for candidate viral oncogenes focused on 
transcriptionally active regions of the MDV genome, genes expressed in transformed 
cells, and identification of genes unique to the MDV-1. Genome comparisons of 
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oncogenic MDV-1, non-oncogenic MDV-2, and MeHV-1 confirmed the Marek’s 
disease putative oncogene meq is unique to the MDV-1 genome. The meq gene is named 
after the EcoQ fragment where it is located, “Marek’s EcoQ”, and two copies are found 
in the viral genome within the terminal repeat long (TRL) and internal repeat long (IRL) 
regions (60, 66, 67, 74, 80). Meq is a 339 amino acid nuclear phosphoprotein that is 
abundantly expressed in MDV transformed cells. The structure of Meq is well defined. 
Meq contains nuclear and nucleolar localization signals a bZIP (basic-region leucine 
zipper) domain and a proline rich transactivation domain (38, 46, 62). The bZIP domain 
of Meq shares significant homology, with the protooncogene c-Jun, a transcription factor 
of the AP-1 (activating protein) complex (33). AP-1 transcription factors are well-
described proteins that include the Jun, Fos and ATF/CREB families. AP-1 proteins are 
characterized by their ability to bind and regulate sequence specific gene elements, AP-1 
sites (5'-TGAG/CTCA-3'), which are found in many genes associated with cell 
proliferation (73). Transformation by deregulated expression of c-Jun, c-Fos and their 
viral counterparts v-Jun and v-Fos is well documented.  The shared homology between 
Meq and c-Jun suggests Meq may transform through similar mechanisms (53, 84, 86).  
A considerable amount of in vitro data supports the oncogenic nature of Meq, 
which has been shown to promote anchorage-independent growth, cell-cycle 
progression, and is anti-apoptotic (48, 49). More recently, in vitro expression of Meq 
was shown to upregulate genes similar to those upregulated by v-Jun, suggesting that 
Meq transforms via a v-Jun transforming pathway (41). Yet, the most convincing 
evidence for Meq’s oncogenic property in MDV transformation was the characterization 
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of a Meq null recombinant MDV virus (rMd5∆Meq), which replicated in chickens but 
did not induce tumors. The essential role of Meq in MDV transformation has been 
further supported by generation of Meq mutant viruses, such as Meq C-terminal binding 
mutant (pRB-1B-Ct20) and more recently Meq homodimer mutant virus (rMd5-
MeqGCN) both of which are non-oncogenic (8, 77). 
Like c-Jun, Meq can both homodimerize and heterodimerize and has the ability 
to dimerize with c-Jun, Fos, Creb and ATF members (42). It is well known that the 
leucine zipper region of bZIP proteins determines the dimerization partners of bZIP 
proteins, which in turn are important determinants of DNA binding specificity and 
therefore transcriptional regulation. For example, different c-Jun dimers have been 
shown to play distinct roles in transformation, i.e. anchorage or serum independent 
growth.  (84). Again, similarly to c-Jun, the DNA binding properties of Meq depend on 
its dimerization partner. Previous characterization of the in vitro DNA binding properties 
of Meq revealed Meq/c-Jun heterodimers bind AP-1 sequences with greater affinity than 
Meq homodimers (42, 61). In addition, Meq and c-Jun were shown to bind AP-1 
sequences, but only Meq was shown by electrophoretic mobility assay (EMSA) to bind 
the sequences contained in the MDV origin of replication (Ori). Transcriptional analysis 
of Meq on the AP-1-like containing meq promoter, and the MDV lytic pp14/38 
bidirectional promoter which contains the MDV Ori, revealed that Meq transactivates 
the meq promoter but represses the bidirectional pp14/38 promoter. Also, Meq has been 
shown to bind the immediate early ICP4 promoter region by chromatin 
immuoprecipitation analysis therefore potentially regulating another lytic gene. This, 
 66 
together with luciferase reporter data, suggests that Meq heterodimers activate AP-1 
containing promoters, therefore potentially activating genes associated with cell 
proliferation, while Meq homodimers may repress genes associated with lytic infection 
and consequently may be involved in regulating lytic or latent infection.  Collectively 
this data points to a role of Meq heterodimers in transformation and Meq homodimers in 
regulation of viral replication.  
In order to delineate the functions of Meq and address the role of Meq 
homodimers in MDV pathogenesis, we recently reported a recombinant Meq mutant 
virus (rMd5-MeqGCN) expressing a chimeric meq gene (MeqGCN), which allowed for 
only Meq homodimer formation. Although this virus replicated in vitro and in vivo, the 
ability to transform T-cells was lost supporting a role for Meq heterodimers in MDV 
transformation. 
In order to evaluate the role of Meq/c-Jun heterodimers in MDV pathogenesis, a 
recombinant virus was constructed that allowed for the exclusive formation of Meq/c-
Jun heterodimers by substituting the parental Meq leucine zipper with that of the leucine 
zipper of c-Fos (MeqFos). The leucine zipper region of c-Fos allows for the formation of 
only heterodimers thus conferring heterodimerization of MeqFos. The DNA binding and 
transactivation/repression properties of MeqFos were tested in vitro. Recombinant virus 
expressing MeqFos was studied in vitro and in vivo and compared to parental rMd5. An 
additional virus was recovered rMd5-MeqFos/GCN, which contains one copy of the 
previously described meqGCN gene and one copy of meqFos and was also included with 
in vivo studies. rMd5-MeqFos replicated similarly to parental rMd5 in vitro; however, 
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infection of chickens with rMd5-MeqFos did not result in gross tumor formation but pre-
neoplastic nerve lesions were observed. Interestingly, paralysis and neoplastic MDV 
lesions were observed with chickens infected with rMd5-MeqFos/GCN. We, therefore, 
present the first in vivo evidence that both Meq homodimers and heterodimers contribute 
in MDV transformation. 
 
Materials and methods 
 
Cells and viruses  
Primary duck embryonic fibroblasts (DEF) were used for virus propagation, virus 
reactivation assay, growth curves and DNA transfections. Cosmids derived from a very 
virulent MDV strain, Md5 were used to generate recombinant viruses (64). Revertant 
virus (rMd5-MeqFosR) was recovered in chicken embryonic fibroblasts (CEF). The DF-
1 cell line was used for luciferase assays, chromatin immunoprecipitation (ChIP) and co-
immunopreciptation (co-IP) experiments (35). Both DEF and CEF were maintained in 
Leibowitz-McCoy (LM) media supplemented with 5% bovine calf serum (BCS) and 
penicillin-streptomycin at 37°C. DF-1 cells were maintained in LM media supplemented 
with 4% fetal bovine serum (FBS) and penicillin-streptomycin at 37°C. 
 
Cosmids 
Previously described cosmids, SN5, P89, SN16, A6 and B40, encompassing the 
entire genome of the very virulent strain Md5 (64) were used to generate a recombinant 
Md5 (rMd5) virus and a recombinant Md5 with a chimeric Meq gene containing the 
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leucine zipper from c-Fos (rMd5-MeqFos) (Fig. 1).  
Mutations in the meq gene were generated as described previously (77) with the 
following only exception that the primers used for overlapping PCR were specific for the 
c-Fos leucine zipper. Briefly, meq-KpnI, which is located within the EcoQ fragment of 
the Md5 genome and contains the coding sequence for meq nucleotides 1- 385, was 
mutated by a series of subcloning steps and overlapping PCR. Overlapping PCR was 
performed in a combination of three PCR reactions to replace the leucine zipper region 
of meq with the leucine zipper region of c-Fos. Two primary PCR reactions were 
performed to generate the 5’ and 3’ ends of meqFos-KpnI fragment. The 5’ reaction was 
performed using primers M13R (5’- CAG GAA ACA GCT ATG AC -3’) and SR1194-
Fos Leucine Zipper Reverse (5’- CTC CGC CTG CAG AGC GGA CTT CTC CTC 
CTC CAG CTG GTC CGT CTC CGC CTG CAG TTT GTC TAC ATA GTC CGT 
CTG CTT CCT -3’).  The 3’ end PCR reaction was performed using primers SR1190 
(5’- GAC CGA GAT AGG GTT GAG TG -3’) and SR1195-Fos Leucine Zipper 
Forward (5’- GAG AAG TCC GCT CTG CAG GCG GAG ATA GCC AAC CTG CTG 
AAG GAG AAG GAG AAG CTG CGT GTA CAG TTG GCT TGT CAT GAG CCA-
3’). Both amplicons were gel purified, mixed together and used as templates in a third 
PCR reaction with primers M13R and SR1190, generating a full meq-KpnI fragment 
containing the Fos leucine zipper in place of the meq leucine zipper (meq-Fos-KpnI). 
The meqFos-KpnI fragment was cloned into the EcoQ fragment, generating EcoQ-
MeqFos, which was subsequently cloned into cosmids A6∆EcoQ and SN5∆EcoQ using 
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recA assisted restriction endonuclease digestion (RARE) yielding cosmids SN5-MeqFos 
and A6-MeqFos.  
 
Transfections 
Viral inserts were released from parental and mutant cosmid DNA by digestion 
with NotI, and purified by phenol chloroform extraction and ethanol precipitation before 
transfection. The calcium phosphate procedure was used to transfect 1.2 x106 DEF in 60 
mm dishes with 500 ng of cosmids P89, SN16, and B40 in combination with SN5 and 
A6, or SN5-MeqFos and A6-MeqFos, or SN5-MeqFos and A6-MeqGCN, to generate 
rMd5, rMd5-MeqFos, and rMd5-MeqFos/GCN, respectively. Five days after 
transfection, cells were trypsinized and seeded onto DEF monolayers and monitored for 
cytopathic effects. Viral stocks of recovered viruses were subsequently made and titrated 
in DEF for further analysis. 
 
Southern blot 
DNA from rMd5 and rMd5-MeqFos infected DEF was isolated by proteinase K 
digestion followed by phenol-chloroform extraction and ethanol precipitation. Three 
micrograms of each DNA sample was digested with either EcoRI or PstI, separated on a 
1% agarose gel, and transferred to nylon membranes. 32P-dCTP-labeled probes 
representing the complete MDV genome (cosmids SN5, P89, SN16, A6 and B40) or 
EcoQ fragment (2,456 bp) were generated by random priming using High Prime DNA 
Labeling Kit (Roche) and were used to hybridize to viral DNA, using standard protocols 
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(68). 
 
RT-PCR 
PCR was performed with primers SR1118 and SR3074 or SR3075 in order to 
confirm expression of the presence of meqFos and meqGCN genes from DEF infected 
with rMd5-MeqFos/GCN. Total RNA was extracted using RNAqueous®-4PCR 
(Ambion). The reverse transcriptase reaction was performed using equal amounts of 
RNA followed by PCR. Four µl of cDNA were used for subsequent PCR reactions using 
primers SR1118-meq start primer (5’-GAT CCC GGG GAG ATG TCT CAG GAG 
CCA GAG C-3’) and leucine zipper specific primers SR3075-Fos leucine zipper (5’- 
TTC AGC AGG TTG GCT ATC -3’), or SR3074-GCN4 leucine zipper (5’- CTA ATT 
TCT TTA ATC TGG CAA C -3’). 
 
Revertant virus 
CEF were inoculated with rMd5-MeqFos to obtain viral DNA used for 
transfections. Gel purified parental Md5 EcoQ fragment together with proteinase K 
digested and phenol-chloroform extracted rMd5-MeqFos genomic DNA, were used to 
co-transfect CEF by the calcium phosphate procedure. After viral plaques were evident, 
individual viral plaques were isolated as described (77).The presence of parental meq or 
Fos leucine zipper sequences from individual plaques were detected by PCR using the 
following primers: SR1118-meq start primer and leucine zipper specific reverse primers 
SR3073-meq leucine zipper (5’- GTC CTT AGA TCT CGA ATT TCC -3’) or SR3075-
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Fos leucine zipper, for parental and Fos leucine zippers, respectively. 
 
Indirect immunofluorescence assay (IFA) and immunohistochemistry (IHC) 
Confluent DEF monolayers were infected with rMd5 or rMd5-MeqFos, and 
when viral plaques were apparent, cells were fixed with ice-cold acetone/alcohol (6:4) 
and Meq expression evaluated by IFA using rabbit polyclonal anti-Meq antibodies 
(1:300). Lymphocytes collected for reactivation assays were deposited on a microscope 
slide using a cytospin centrifuge, fixed with ice-cold acetone/alcohol (6:4) and 
expression of pp38 evaluated by IFA using the H19 pp38 specific monoclonal antibody 
(1:400). For IHC, lymphoid organs (thymus, spleen and bursa of Fabricius), and feather 
follicles from infected and uninfected chickens were embedded in optimal cutting 
temperature compound (Tissue-Tek, OCT, Sakura Finetek, Torrance, CA), immediately 
frozen in liquid nitrogen and stored at -80°C until use. Six- to 8-µm-thick cryostat 
sections of tissue were prepared and fixed with cold acetone at -20°C for 5 min, and air-
dried. Immunostaining was carried out using H19 pp38 monoclonal antibody (1:3000) 
and the Vectastain ABC kit (Vector Laboratories, Burlingame, CA) according to the 
manufacturer’s instructions. 
 
Luciferase assays 
The transactivation/repression activity of the MeqFos protein on MDV promoters 
was evaluated by luciferase assay. The previously described meq, pp38, pp14 and MDV 
Ori promoter constructs (77) were used for luciferase assays. Meq, MeqFos, and c-Jun 
 72 
genes were cloned into the pcDNA 3.1 Zeo vector (Invitrogen) to generate expression 
vectors, pcDNA-Meq, pcDNA-MeqFos, and pcDNA-Jun. DF-1 cells (1X105) were 
seeded in 12-well plates 16 hr prior to transfection and incubated at 37°C under standard 
conditions. Transfections were performed using siPORT XP-1 (Ambion), 500 ng of 
pcDNA (empty vector control), pcDNA-Meq, pcDNA-MeqFos, or 250 ng of pcDNA-
Jun with either 250 ng of pcDNA-Meq or pcDNA-MeqFos, and either 250 ng of pGL3-
meq, pGL2-Ori, or pGL3-pp14 or pGL3-pp38 promoters. Cell lysates were harvested 48 
hours post-transfection with active lysis buffer (Promega) and luciferase assay 
performed using a Biotek Clarity luminometer (Biotek, Winooski, VT). The protein 
concentration in each transfected sample was measured by Bradford assay (Bio-Rad, 
Hercules, CA) and luciferase activity was normalized to protein concentration. Assays 
were performed in triplicate and three independent experiments were performed for each 
reporter vector tested. Transactivation or transrepression activity was expressed as the 
fold differences relative to empty pcDNA vector control. Results of all three experiments 
were analyzed by one-way ANOVA followed by Tukey HSD test using the  SPSS®, 
Version 14.0 software (SPSS Inc., Chicago, IL, USA). For all analysis, p ≤ 0.05 was 
considered statistically significant. 
 
Chromatin immunoprecipitation assay (ChIP) 
DF-1 cells (1.5 X 106) were seeded in 100 mm dishes 16 hrs prior to transfection 
with pcDNA (empty vector control), pcDNA-Meq, or pcDNA-MeqFos and pGL2-3XOri 
and pGL3-meq promoter using siPORT XP-1. ChIP assays were carried out essentially 
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as described (52) with the following modifications. Briefly, cells were trypsinized, 
trypsin was neutralized with DF-1 growth media, and cells were pelleted by 
centrifugation. Cell pellets were resuspended in 10 ml fresh media and cell suspensions 
were cross-linked in 1% formaldehyde (v/v) at 37°C for 10 min. The cross-linking 
reaction was stopped by the addition of glycine at a final concentration of 125 mM for 5 
minutes at RT. The fixed cell suspensions were pelleted by centrifugation and washed 
two times in PBS. After the second wash, cell pellets were resuspended in SDS-lysis 
buffer (50 mM Tr-s-HCl, pH8.1, 1% SDS, 10 mM EDTA), sonicated on ice, and diluted 
with ChIP dilution buffer (16.7 mM Tris-HCl, pH8.1, 0.01% SDS, 1.1 % Triton X-100, 
1.2 mM EDTA, 167 mM NaCl) containing 1x Complete Protease Inhibitor Mixture 
(Roche). Chromatin was cleared twice by incubation with Protein G agarose/salmon 
sperm DNA bead slurry (Millipore, Billerica, MA) at 4 °C for 30 min, followed by 
centrifugation. Ten µl of anti-Meq antibody or 1 µg of rabbit-IgG was added to the 
cleared chromatin and incubated at 4 °C overnight with mixing. Chromatin was 
precipitated with Protein G agarose/salmon sperm DNA bead slurry 1 h at 4 °C with 
mixing. The agarose beads were recovered and washed successively for 5 min at 4 °C in 
low salt, high salt, LiCl and TE buffers. Chromatin was eluted in freshly prepared elution 
buffer (1% SDS, 0.1 M NaHCO3) at room temperature for 15 min. Samples were treated 
with RNase A and cross-linking was reversed by incubation at 65 °C for 4 h. Chromatin 
was ethanol precipitated and  proteinase K digested. The precipitated DNA was purified 
using Purelink PCR purification kit (Invitrogen) and eluted in 50 µl of sterile water. PCR 
detection of pGL2-3XCACA and pGL3-MSP plasmids was performed in 25-µl reactions 
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containing 2 µl of chromatin and primers pGL2-ChIP-F1 (5'-CCC CCT GAA CCT GAA 
ACA TA-3') and pGL2-ChIP-R1 (5'-GCC TTA TGC AGT TGC TCT CC-3'); pGL3-
ChIP-F1 (5’-GTG GCT TTA CCA ACA GTA CC-3’) and pGL3-ChIP-R1 (5’-GCT 
CTC CAT CAA AAC AAA AC- 3’), respectively. PCR amplification was performed 
with an initial denaturation at 95 °C for 3 min followed by 23 cycles of 95 °C for 30 s, 
50 °C for 30 s, and 72 °C for 30 s followed by a final elongation step at 72 °C for 5 min.  
Colony formation in soft agar 
DF-1 cells were transfected with pcDNA, pcDNA-Meq or pcDNA-MeqFos using 
siPORT XP-1 (Ambion). Approximately 48 hours after transfection, the transfected DF-
1 cells were selected with 300 µg/ml zeocin (Invitrogen) for 4 weeks. Expression of Meq 
was confirmed by IFA using rabbit anti-Meq antibodies as described above. Pools of 
resistant cells (5 X103) were seeded in 0.33% agarose containing LM media with 150 
µg/ml zeocin and 10% FBS overlaid on a 0.5% agarose in a 35-mm plate. After 3 weeks 
of culture, colonies were examined under a light microscope and photographed using 12 
X magnification. Three different fields were randomly selected and colonies greater than 
100 µm were counted. Two independent experiments were performed and each 
experiment was performed in triplicate. 
 
In vitro growth kinetics 
To compare the growth characteristics of rMd5 and rMd5-MeqFos, DEF seeded 
on 35 mm plates were inoculated with approximately 50 plaque forming units (PFU) of 
each virus. On days 2, 4 and 6 post inoculation, the infected cells were trypsinized, serial 
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dilutions inoculated onto 35 mm plates seeded with fresh DEF and plaques at the 
different dilutions counted 7 days later. 
 
Pathogenesis experiments 
Experiment 1 
To study the effect of Meq heterodimers on viral replication, 4-week-old SPF 
chickens (Hy-Vac, Adel, Iowa) were randomly sorted into experimental groups of nine 
chickens each. One group remained as a non-inoculated control, whereas the other 
groups were inoculated subcutaneously with 3,000 PFU of rMd5 or rMd5-MeqFos. At 
14 and 21 days post infection (dpi), blood samples, from randomly selected chickens, 
were collected in heparin for reactivation assays (see below), and were subsequently 
euthanized for tissue sample collection. At 6 and 21 dpi lymphoid organs and feather 
follicles were collected for IHC, respectively.  
 
Experiment 2 
To study the role of the Meq heterodimers on oncogenesis, SPF day old chicks 
(ten per group) were inoculated subcutaneously with 2,000 PFU of rMd5, rMd5-
MeqFos, or rMd5-Meq/Fos/GCN and reared in modified Horsfall-Brauer isolation units 
for 8 weeks. Weekly mortality was recorded and all chickens were necropsied at time of 
death or at termination of the experiments (8 weeks) and evaluated for MD specific 
lesions in the viscera and the nerves. Blood was also collected from three randomly 
selected chickens from each group for reactivation assays at day 37 dpi.  
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Experiment 3 
To study the role of Meq heterodimers on horizontal transmission, six SPF 
(Charles River) day old chicks were inoculated subcutaneously with 3,000 PFU of rMd5 
or rMd5-MeqFos while three additional uninoculated chicks were reared with each 
group and served as contacts to assess horizontal transmission. At 8 weeks post 
inoculation buffy coats were obtained from heparinized blood by centrifugation at 500 X 
g. DNA was extracted using Purelink Genomic DNA extraction kit (Invitrogen) and 
PCR was performed using MDV specific Meq primers SR1118 (5’-GAT CCC GGG 
GAG ATG TCT CAG GAG CCA GAG C-3’) and SR1135 (5’-GAT CCC GGG TCA 
GGG TCT CCC GTC ACC TGG AAA CC -3’) to detect the presence of MDV genome.  
 
Reactivation assay 
Buffy coats were collected as described above at 14, 21, and 37 dpi. DEF 
monolayers seeded in 35 mm plates were inoculated with 106 lymphocytes in duplicate 
and viral plaques counted 7 days post inoculation. 
 
Results  
 
Meq heterodimer mutant (MeqFos) retains DNA binding, transactivation and repressive 
functions 
Like the Jun family of bZIP transcription factors, Meq has the ability to form 
homodimers and heterodimers (42). It is well known that the specific amino acid 
residues within the leucine zipper of bZIP proteins determine their dimerization 
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properties. Among these transcription factors, c-Fos has been extensively studied and it 
is known that the leucine zipper of c-Fos exclusively forms heterodimers with the Jun 
family of transcription factors (26, 37, 63). Similar to other studies (15, 26, 27, 34, 63), 
we utilized the leucine zipper region of c-Fos in place of the parental leucine zipper of 
Meq to study the function of Meq/Jun heterodimers in MDV pathogenesis.  The leucine 
zipper of meq was successfully “swapped” with the leucine zipper of c-fos using 
overlapping PCR, resulting in a Meq heterodimer mutant, MeqFos (Fig. 14).  
 
 
 
 
Fig. 14. Schematic representation of the meq gene and meq and fos leucine zippers (LZ). 
The DNA binding basic regions (BR1 and BR2) and transactivation domains, are 
depicted. The LZ sequence of parental meq and c-Fos used to replace parental meq LZ in 
rMd5-MeqFos are shown. Asterisks indicate the conserved leucine sites. 
  
The open reading frames of meq and meqFos were cloned into the pcDNA 
expression vector. Previous work has shown that Meq homodimers and heterodimers 
have different DNA binding affinities. Although both Meq homodimers and 
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heterodimers bound AP-1 sequences, Meq together with c-Jun bound AP-1 sequences 
with greater affinity than Meq alone.  In addition, Meq alone bound the MDV origin of 
replication (MDV Ori) located in the pp38/14 bidirectional promoter by EMSA analysis 
(42). Luciferase reporter assays indicated functional differences between Meq and Meq 
plus c-Jun in that although Meq activated the AP-1 containing meq promoter, Meq plus 
c-Jun resulted in higher activation. Furthermore, Meq expression was shown to repress 
the MDV pp38/pp14 bidirectional promoter which contains the MDV Ori (42). 
Therefore, chromatin immunoprecipitation (ChIP) and luciferase assays were performed 
to test the DNA binding and transactivation/repression functions of MeqFos. 
Luciferase assays were utilized to test the transactivation and repressive 
functions of MeqFos compared to parental Meq. DF-1 cells were transfected with 
pcDNA empty vector, pcDNA-Meq, pcDNA-MeqFos, pcDNA-c-Jun, or a combination 
of pcDNA-Meq, pcDNA-MeqFos, and pcDNA-c-Jun, together with reporter vectors 
pGL3-meq, pGL3-pp14, pGL3-pp38, or pGL2-3X-Ori.  As shown in figure 15, both 
Meq and MeqFos activate the meq promoter, however MeqFos required co-transfection 
with pcDNA-c-Jun for transactivation, therefore indicating heterodimerization MeqFos 
with c-Jun is required for transactivation. Unexpectedly, both Meq and MeqFos 
repressed pp38 and pp14 promoters (Fig. 15). In addition, both Meq and MeqFos 
repressed the pGL2-3X-Ori reporter, which contains three copies of the sequence 
element found in the pp38/14 bidirectional promoter that Meq homodimers was 
previously reported to bind (42, 61).  
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Fig. 15. Luciferase assays demonstrate that MeqFos has functional transactivation and 
repression activities. DF-1 cells were transfected with meq-promoter, pp14 promoter, 
pp38 promoter or 3X-Ori luciferase reporter plasmids and pcDNA (empty vector), 
pcDNA-Meq, pcDNA-MeqFos, or pcDNA c-Jun, with or without c-Jun. Both Meq and 
MeqFos activate the meq-promoter and repress the pp38/14 bidirectional promoters and 
3X-Ori. However, activation of the meq promoter by MeqFos requires c-Jun. Luciferase 
values are expressed as fold difference relative to pcDNA vector. Significance (*) equals 
p ≤ 0.05. Error bars indicate SD. 
 
In order to evaluate the DNA binding capacity of Meq and MeqFos ChIP assays  
were performed. DF-1 cells were transfected simultaneously with pGL3-meq promoter 
and pGL2-3X-Ori, along with pcDNA empty vector, pcDNA-Meq or pcDNA-MeqFos 
with or without pcDNA-c-Jun. As expected, Meq bound both the meq promoter and 
MDV Ori and MeqFos also bound the meq promoter. However, in contrast to previous 
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EMSA data MeqFos was also able to bind the 3X-Ori. In addition, DNA binding by both 
Meq and MeqFos was enhanced when cells were transfected with pcDNA-c-jun 
(Fig.16).  
 
Fig. 16. Chromatin Immunoprecipitation (ChIP) analysis was performed to test the DNA 
binding capacity of of Meq and MeqFos on the meq promoter and 3X-Ori construct, 
which contains three repeats of the CACA Meq binding site. Both Meq and MeqFos 
were recruited the meq promoter and 3X-Ori, and transfection with pcDNA-c-Jun 
increased binding.  
 
Colony formation in soft agar 
Colony formation in soft agar is a marker of transformation and Meq expression 
in fibroblasts has been shown to promote anchorage independent growth (41). Soft agar 
assay was employed to test the ability of Meq heterodimers to promote colony formation 
in soft agar. Meq and MeqFos expression in selected DF-1 cells was confirmed by IFA 
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(Fig. 17a top panel). As expected, selected DF-1 cells expressing the pcDNA-Meq 
construct formed large colonies in soft agar when compared to control cells selected with 
pcDNA empty vector (Fig. 17a bottom panel). Furthermore, cells expressing pcDNA-
Meq had 25 X more colonies >100 µm in size compared to pcDNA control cells. In 
contrast, DF-1 cells expressing pcDNA-MeqFos only had 3.5 X as many colonies >100 
µm in size compared to empty vector control cells (Fig. 17b), indicating that MeqFos 
heterodimers have a reduced potential for anchorage independent growth. 
 
 
Fig. 17. In vitro soft agar assays demonstrating that MeqFos has reduced transformation 
potential. (a) Top panel: Immunofluorescence analysis of Meq expression from pools of 
selected DF-1 cells transfected with pcDNA, pcDNA-Meq, pcDNA-MeqFos. Bottom 
panel: Soft agar assay was performed using pcDNA, pcDNA-Meq, pcDNA-MeqFos 
selected DF-1 cells to assess anchorage independent growth. (b) Number of colonies > 
100 µm observed in cells expressing pcDNA, pcDNA-Meq, or pcDNA-MeqFos. 
Average number of colonies counted from three random fields are shown. Error bars 
indicate SD. 
 
 
Construction of a Meq-heterodimer mutant virus rMd5-MeqFos 
A recombinant Md5 mutant virus in which the leucine zipper region of meq was 
replaced with the corresponding region of Fos (rMd5-MeqFos) was successfully 
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constructed. The leucine zipper region of the meq gene was replaced with the leucine 
zipper region of Fos by overlapping PCR, and the EcoQ fragment containing the 
chimeric meqFos gene was cloned into the A6∆meq and SN5∆meq cosmids. The 
resultant cosmids A6-MeqFos and SN5-MeqFos together with cosmids P89, B40 and 
SN16 were cotransfected into DEF by the calcium phosphate method and a recombinant 
virus was subsequently recovered by homologous recombination. In addition, rMd5-
MeqFos/GCN was recovered by cotransfection of cosmids P89, B40, SN16, SN5-
MeqFos and previously described cosmid A6-MeqGCN. Southern blot analyses were 
performed to assess the integrity of the rMd5-MeqFos viral genome.  Genomic DNA 
from rMd5 and rMd5-MeqFos infected DEF was digested with EcoRI or PstI and probed 
with 32P labeled Md5 comids or EcoQ fragment DNA, respectively.  No differences 
were observed between rMd5 and rMd5-MeqFos EcoRI and PstI digestion patterns 
confirming the integrity of the recombinant genomes (Fig. 18a). RT-PCR was performed 
to confirm mRNA expression of MeqFos and MeqGCN from DEF infected with 
rMd5MeqFos/GCN (Fig. 18b). 
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Fig. 18. Southern blot and RT-PCR analysis of recombinant viruses. a) Southern blot 
analysis of rMd5 and rMd5-MeqFos. Both rMd5 and rMd5-MeqFos DNA was digested 
with EcoRI, or PstI and probed with total viral MDV DNA, or EcoQ fragment, 
respectively. The restriction profile of rMd5-MeqFos is similar to that of rMd5, 
indicating no gross genome rearrangements incurred. b) RNA isolated from rMd5, 
rMd5-MeqFos, and rMd5-MeqFos/GCN infected DEF was isolated and RT-PCR with 
Meq start and leucine zipper specific primers performed, generating a 320 amplicon.  
 
Immunofluorescence assay (IFA) was performed to evaluate Meq expression in 
virus infected DEF. Meq expression was detected in both rMd5, rMd5-MeqFos, and 
rMd5-MeqFos/GCN infected DEF but not in uninfected cells (Fig. 19).  
 84 
 
Fig. 19. Immunofluorescence analysis of DEF cells infected with recombinant viruses. 
Uninfected DEF, rMd5-Meq infected DEF, rMd5-MeqFos infected DEF, rMd5-
MeqFos/GCN infected DEF, at 100X magnification.  
 
In vitro and in vivo replication of rMd5-MeqFos 
The in vitro growth properties of rMd5-MeqFos were tested, to assess if the 
leucine zipper mutations had any effect on virus replication in vitro. Our results indicate 
that rMd5 and rMd5-MeqFos virus replicated similarly at the time points tested (days 0, 
2, 4, 6) (Fig. 20).   
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Fig. 20. In vitro growth properties of rMd5 and rMd5-MeqFos. DEFs were infected with 
the indicated viruses, harvested on days 2, 4 and 6 after infection and titered on fresh 
DEF. Day 0 indicates the titer of the virus in the inoculum. The experiment was 
performed in duplicate, and the titer (logarithm of the mean number of plaque-forming 
units per dish) is indicated. 
 
To test the role of Meq heterodimers during in vivo replication, 4-week-old SPF 
chickens were inoculated with 3,000 pfu of rMd5 or rMd5-MeqFos. Six days after 
inoculation two randomly selected birds were euthanized and lymphoid organs (thymus, 
spleen and bursa of Fabricius) collected and evaluated for viral lytic antigen (pp38) 
expression by IHC. Expression of pp38 was present in bursa of Fabricius (Fig. 21) 
thymus and spleen (data not shown) of both rMd5 and rMd5-MeqFos infected chickens, 
indicating that the leucine zipper mutations in the rMd5-MeqFos virus did not affect 
early cytolytic infection.  
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Fig. 21. Infection of lymphoid tissue and feather follicles of chickens infected with rMd5 
and rMd5-MeqFos. Immunohistochemistry of bursa of Fabricius and feather follicles, 6 
and 21 dpi, respectively using anti-pp38 monoclonal antibody (H19). Positive cells are 
indicated by brown staining, counterstaining was performed with hematoxylin. 
 
MDV switches from an active cytolytic infection to a latent infection 
approximately 7-8 days PI and virus reactivation can be observed when latently infected 
lymphocytes are co-cultured with fibroblasts (11).  To examine if Meq homodimers are 
involved in the establishment of latency and reactivation, peripheral blood lymphocytes 
(buffy coats) were obtained from three chickens from each group on days 14 and 21 PI 
and co-cultured with DEF.  To confirm viral infection, portions of collected lymphocytes 
were fixed on microscope slides and IFA performed to detect viral antigen, pp38 (Fig. 
22).  
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Fig. 22. Detection of MDV pp38 protein in latently infected cells 21 dpi. 
Immunofluorescence assay was performed with anti-pp38 monoclonal antibody (H19) 
on PBMC’s collected from rMd5 and rMd5-MeqFos infected chickens. Texas-red 
conjugated secondary antibodies were used to detect pp38 and nuclei were stained with 
DAPI. 
 
IFA confirmed expression of pp38 from infected lymphocytes at day 21 PI (Fig. 
22) although reactivated virus was not recovered from co-culture with DEFs. PBMC’s 
were also collected for reactivation assays at day 37 PI from infected chickens used for 
experiment 3. As shown in Table 3, none or few reactivated viral plaques were obtained 
from PBMCs of chickens infected with rMd5-MeqFos days 14 days and 21 PI. However, 
reactivated virus comparable to rMd5 was obtained at day 37 PI from one out of three 
chickens from both rMd5-MeqFos and rMd5-MeqFos/GCN infected chickens (Table 3).  
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Table 3. 
Virus reactivation from peripheral blood lymphocytes 
 
Group Day 14 Day 21 Day 37* 
rMd5 
121 
181 
75 
28 
120 
123 
116.5 
118.5 
129 
rMd5-MeqFos 
0 
1 
5 
0 
0 
0 
2.5 
8 
133.5 
rMd5-MeqFos/GCN ND ND 
1.5 
4 
158 
Reactivation assays were performed on days 14, 21 and 37* after inoculation. 
The numbers represent the average number of pfu observed when106 
peripheral blood lymphocytes were co-cultured with DEF from each chicken in 
duplicate. * Samples were collected from chickens from experiment 2.  
 
 Transmission of MDV occurs after viral replication in feather follicle epithelium 
(FFE) and release of infectious dander (13). Therefore, to assess if the rMd5-MeqFos 
heterodimer mutant was able to replicate in the FFE, expression of the lytic viral antigen 
pp38 was evaluated in three chickens from each inoculated group by IHC. Tissues from 
both rMd5 and rMd5-MeqFos infected groups tested positive for pp38 antigen indicating 
the ability of rMd5-MeqFos, like rMd5, to replicate in the FFE (Fig. 21). To further 
evaluate MDV transmission, day old SPF chickens were inoculated with 3,000 pfu of 
rMd5 or rMd5-MeqFos and housed with three uninfected contact chicks. Buffy coats 
were collected from contact birds 8-weeks PI, DNA extracted and PCR for Meq 
performed (data not shown). Transmission to contact birds was confirmed by PCR in 
two chickens infected with rMd5 and all three contact chickens infected with rMd5-
MeqFos were PCR positive for meq (data not shown). Altogether these results confirm 
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that rMd5-MeqFos retains the ability to transmit horizontally by shedding through the 
FFE. 
 
Oncogenecity of rMd5-MeqFos 
To determine if Meq-Jun heterodimers are sufficient for in vivo transformation of 
T-cells, groups of nine SPF chickens were inoculated at day of age with 2,000 pfu of 
rMd5, rMd5-MeqFos, or rMd5-MeqFos/GCN and observed for mortality for a period of 
8 weeks. All chickens that died during the experiment or were euthanized at the 
termination of the experiment were evaluated for MDV-specific lesions. MDV-
associated mortality was observed in rMd5-infected chickens starting at week 4 PI and 
none of the chickens survived to the end of the experiment. Preneoplastic lesions only 
were observed in the rMd5-MeqFos group while 20% of chickens infected with rMd5-
MeqFos/GCN contained neoplastic lesions and 60% contained preneoplastic lesions. 
Paralysis was observed in rMd5-MeqFos/GCN infected chickens containing neoplastic 
nerve lesions. In addition one out of three contact chickens from the rMd5-MeqFos/GCN 
infected group contained preneoplastic nerve lesions while none were observed in the 
contact chickens of the rMd5-MeqFos group.  
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Fig. 23. MDV induced preneoplastic and neoplastic nerve lesions from chickens infected 
with rMd5, rMd5-MeqFos and rMd5-MeqFos/GCN. Neoplastic nerve lesions were 
observed in rMd5 and rMd5-MeqFos/GCN infected chickens while preneoplastic lesions 
were observed in chickens infected with rMd5-MeqFos. 
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Table 4.  
Pathogenicity of rMd5, rMd5-MeqFos, rMd5-MeqFos/GCN and  
rMd5-MeqFosR in SPF MDV maternal antibody-negative chickens 
Histological Lesions (%)b 
 Virusa 
 
MDV 
Mortality (%) 
Preneoplastic Neoplastic 
rMd5 10/10 (100) ND ND 
rMd5-MeqFos 0/10 (0) 4/8 (50) 0/0 (0) 
rMd5-MeqFosRc 3/3 (100) ND ND 
rMd5-MeqFosGCN 2/10 (20) 6/10 (60) 2/10 (20) 
Uninfected 0/8 (0) 0/3 (0) 0/3 (0) 
aAll chickens were inoculated with 3,000 PFU of the indicated viruses. 
bChickens that were not positive for gross tumors were further evaluated for 
microscopic tumors 
c Performed as an independent experiment 
 
Construction and Biological Properties of Revertant Virus rMd5-MeqFosR  
To verify that the phenotypic changes observed with rMd5-MeqFos were due to 
changes introduced in the leucine zipper region, a revertant virus was constructed. DNA 
obtained from rMd5-MeqFos infected CEF was co-transfected with purified parental 
MDV EcoQ DNA, which contains the meq gene. A revertant virus, rMd5-MeqFosR, was 
selected by plaque purification, and screened for the presence of both parental meq and 
mutant meqFos genes by PCR. PCR revealed that of the 102 plaques tested, one 
contained one copy of the parental meq gene restored in the viral genome. Three 
 92 
chickens were infected with 3,000 pfu of rMd5-MeqFosR and by week 5 PI all three 
were positive for MDV gross tumors, confirming that the attenuated phenotype of rMd5-
MeqFos was due to the mutations introduced in the leucine zipper of Meq.  
 
Discussion 
In this study, the role of Meq-Jun heterodimers in MDV transformation was 
investigated to complement our recent investigations evaluating Meq/Meq homodimers 
in MDV pathogenesis using a recombinant Meq homodimer (rMd5-MeqGCN) virus. We 
found that rMd5-MeqGCN is non-oncogenic, supporting the concept that Meq/c-Jun 
heterodimers cooperate in transformation. The results of the current study further dissect 
the functions of Meq homodimers and heterodimers in MDV pathogenesis by evaluating 
the Meq-Jun partnership in vivo and we demonstrate that both Meq homodimers and 
heterodimers contribute in MDV transformation. 
In order to assess the functions of Meq-Jun heterodimers in MDV pathogenesis, a 
recombinant virus in which the leucine zipper of the Meq protein was replaced with the 
leucine zipper of c-Fos was successfully generated. It is well established that the leucine 
zipper region of bZIP proteins determines their dimerization specificity, and that c-Fos 
exclusively heterodimerizes with the Jun family of transcription factors (37, 63, 84). In 
addition, the modular nature of bZIP proteins allows the leucine zipper region to be 
“swapped” among bZIP proteins generating chimeric proteins that allow for the 
characterization of specific bZIP dimers (15, 27, 34, 63, 72).  
The DNA binding, transactivation/repression, and transformation properties of 
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MeqFos were evaluated in vitro. Previous in vitro characterization of Meq DNA binding 
and transactivation/repression activities have indicated that Meq homodimers and 
heterodimers differ in DNA binding and therefore transcriptional activity, thus implying 
Meq homodimers and heterodimers may have distinct roles in MDV-1 pathogenesis (33, 
41, 42, 61). Therefore, the DNA binding and transactivation/repression activities of 
MeqFos were tested in vitro.  
As expected parental Meq alone or with c-Jun significantly activated the meq 
promoter. In addition, MeqFos together with c-Jun activated the meq promoter, thus 
supporting that the leucine zipper mutations conferred heterodimerization with c-Jun 
(Fig. 15). In addition, ChIP assays confirmed that MeqFos was recruited to the meq 
promoter, and binding was enhanced by cotransfection with c-Jun (Fig. 16).  This 
implies that Meq homodimers were able to activate the Meq promoter in the absence of 
exogenous c-Jun, or that Meq partnership with ATF/CREB members may activate the 
Meq promoter. Nonetheless, Meq/c-Jun heterodimers have a synergistic effect on 
activation of the Meq promoter, as levels of activation were comparable to Meq alone 
even though half the amount of pcDNA-Meq DNA was used for cotransfection, and 
pcDNA-c-Jun did not activate the Meq promoter independently (Fig. 15). We recently 
described that the vaccine strain of Meq, CVI-Meq, required exogenous c-Jun for 
activation of the Meq promoter. This observation may reflect that even though the 
leucine zipper is identical between Md5 Meq and CVI-Meq, other differences in CVI-
Meq, such as phosphorylation, contribute to preferentially dimerization with c-Jun or 
that CVI-Meq homodimers are inefficient transactivators due to amino acid differences 
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in their transactivation domain (1).  
Unexpectedly MeqFos and c-Jun significantly repressed both pp38 and pp14 
promoters and the 3X-Ori (Fig. 15). Previous characterization of Meq-Jun DNA binding 
sequences (20) demonstrated that Meq together with c-Jun did not bind the MDV Ori 
(42, 61), which is located in the pp38/14 bidirectional promoter, therefore it was 
expected that repression of these reporters was due to Meq homodimers. A number of 
putative transcription factor binding sites have been described in the pp38/14 promoters 
including AP-1, SP-1, CAAT, and c-myc (20). It is possible that Meq and c-Jun may 
repress these promoters by competition for AP-1 sites by other AP-1 dimers (54). 
However, MeqFos and c-Jun repressed the 3X-Ori, although this construct is not a 
relevant promoter, however it contains three tandem repeats of the previously 
characterized Meq binding site located within the MDV Ori (42, 61). Therefore, this 
construct was used to evaluate Meq binding under physiologic conditions by ChIP assay. 
Previous EMSA data using bacterially expressed Meq and c-Jun protein, showed that 
only Meq homodimers bound the “CACA” sequence. However, our observations 
indicate that MeqFos under physiologic conditions is recruited to the 3x-Ori (Fig. 16). 
Nonetheless, our data shows that MeqFos retains transactivation and repressive 
functions, and that transactivation requires excess c-Jun, implying that MeqFos 
exclusively heterodimerizes.   
The ability of MeqFos to promote anchorage independent growth as a marker for 
transformation was evaluated in vitro by soft agar assay. Although numerous colonies 
were observed in DF-1 cells expressing Meq, reduced colony formation was observed in 
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DF-1 cells expressing MeqFos (Fig. 17). This together with previous observations that 
MeqGCN also had reduced colony formation in vitro suggests that both Meq 
homodimers and Meq heterodimers may promote anchorage independent growth or that 
Meq heterodimerization with other AP-1 members outside the Jun family also contribute 
to transformation in vitro. Complementing pathways have been observed for c-Jun 
transformation in vitro. Although, in the case of c-Jun, GCN4 and EB1 Jun chimeric 
proteins transform in vitro and in vivo, the chimeric proteins exhibit increased stability 
over wild type c-Jun proteins and enhance the transforming ability of c-Jun homodimers 
(27, 34). In addition to homodimers contributing to c-Jun transformation, heterodimers 
of c-Jun/Fos and c-Jun/ATF2 activate complementing pathways involved in c-Jun 
transformation (81). Meq also has the ability to dimerize with ATF/CREB family 
members, however the possible contribution of ATF/CREB family members in MDV 
transformation has not been defined (42) but may be of consideration as ATF/CREB 
members have also been implicated in oncogenesis. Upregulation of CREB has been 
described in acute myeloid leukemia and clear cell carcinoma, and is necessary for 
transformation by human T-lymphotropic virus type 1 (HTLV-1) oncogene tax (76), and 
ATF-2 has been shown to promote serum independence in vitro, and contribute to 
growth and progression of mouse skin tumors (83).  
The role of Meq heterodimers in Md5 pathogenesis was investigated by 
evaluating both viral replication, latency/reactivation and transformation properties of 
rMd5-MeqFos in vivo. In vitro, rMd5-MeqFos replicated similar to parental virus and in 
vivo, cytolytic infection was apparent in lymphoid organs and feather follicles as 
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assessed by expression of MDV-1 lytic protein pp38 (Fig. 21). As the FFE is the site of 
fully productive infection and source of horizontal transmission (13), we evaluated 
replication of rMd5-MeqFos in the FFE by IHC (Fig. 21) and transmission to contact 
chickens. Our results show that Meq heterodimerization did not interfere with either 
replication in the FFE or transmission to contact chickens. These results are not 
unexpected as Meq is not required for replication in lymphoid organs or feather follicle 
epithelium (50).  
We previously reported the rMd5-MeqGCN appeared to be defective in 
reactivation and speculated, therefore, that Meq heterodimers may play a role in 
reactivation from latency (77). The switch from lytic to latent infection in MDV-1 
generally occurs approximately 7 days PI, and virus from latently infected cells can be 
reactivated when co-cultured with fibroblasts in vitro (11). Therefore, reactivation assays 
were performed. Like rMd5-MeqGCN, rMd5-MeqFos appeared to have impaired 
reactivation. As none or few viral plaques were reactivated at days 14 and 21 PI (Table 
3) even though the presence of viral infection was confirmed by IFA (Fig. 19). 
Therefore, these results do not support that Meq/c-Jun heterodimers are involved in 
reactivation.  
However, since our assessment was not quantitative, we cannot dismiss the 
possibility of decreased viral loads. Intriguingly, our IFA results show viral pp38 
expression was only detected in dividing cells from PBMC’s. This observation is similar 
to latent infection with EBV in Burkitt’s lymphoma where viral antigen expression was 
only detected in dividing memory B-cells thus supporting a true latent infection where 
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viral proteins are not expressed (28). Interestingly, at day 37 PI one chicken from rMd5-
MeqFos and rMd5-MeqFos/GCN had viremias comparable to parental rMd5 (Table 3). 
To assess if any mutations in the MeqFos and MeqGCN genes incurred which may have 
contributed to higher reactivation numbers observed with these two recovered viruses, 
the MeqFos and MeqGCN genes were sequenced. However, no mutations were detected 
(data not shown). In addition, we evaluated if an association between MDV lesions and 
reactivation was present, but this was not clear as the rMd5-MeqFos infected chicken 
had preneoplastic nerve lesions and only the rMd5-MeqFos/GCN infected chicken had 
neoplastic nerve lesions. Therefore, we can only speculate that host factors may have 
contributed to reactivation in these two chickens. However, a worthwhile follow up 
study would be infection of chickens with the rMd5-MeqFos and rMd5-MeqFos/GCN 
recovered viruses with high reactivation and evaluate if they are more pathogenic, than 
the original inoculums.   
In order to assess the role of the Meq-Jun partnership in MDV transformation in 
vivo, SPF chickens were infected with rMd5-MeqFos and evaluated for MDV specific 
lesions for an eight-week period. An additional virus, rMd5-MeqFos/GCN, which 
contains one copy of MeqFos and one copy of MeqGCN was also included in order to 
investigate if both Meq homodimers and heterodimers contribute to MDV 
transformation in vivo. Preneoplastic nerve lesions were detected in both rMd5-MeqFos 
and rMd5-MeqFos/GCN infected chickens, and 20% of chickens infected with rMd5-
MeqFos/GCN contained neoplastic nerve lesions. However, visceral tumors were not 
observed in either groups, and paralysis was only observed in rMd5 and rMd5-
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MeqFos/GCN infected chickens. These data support that both Meq homodimers and 
heterodimers contribute to T-cell transformation. However, rMd5-MeqFos/GCN clearly 
displayed a phenotype distinct from rMd5, as visceral tumors were not observed and MD 
mortality was significantly reduced. Therefore, Meq homodimers and Meq/Jun 
heterodimers are not sufficient to restore the Md5 phenotype. It is possible that 
interactions of Meq with bZIP proteins such as ATF/CREB contribute to MDV 
pathogenesis. Also interaction of Meq with other unknown cellular factors may have 
been abrogated by replacement of the parental leucine zipper with Fos and GCN leucine 
zippers. Further studies with point mutations in the leucine zipper region rather than 
gross changes may help in further delineating the function of Meq homo and 
heterodimers.  
In summary, this work provides the first in vivo evidence that both Meq 
homodimers and Meq-Jun heterodimers contribute to MDV transformation. Further 
work investigating the role of Meq and ATF/CREB members will help in developing a 
better understanding of the transforming pathways in MDV pathogenesis.  
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CHAPTER IV 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary of research 
The ratinale behind these studies was based on previous characterization of the 
bZIP properties of Meq and the association between Meq and c-Jun in MDV tumor cells.  
In vitro observations indicated differential roles for Meq homodimers and Meq/c-Jun 
heterodimers since they displayed differences in DNA binding based on EMSA analysis 
(42, 61). Further support for the Meq-Jun partnership in MDV transformation was 
demonstrated by upregulation of v-Jun genes by cells expressing Meq, and attenuated 
colony formation in cells expressing Meq when c-Jun is silenced (41). Therefore the 
hypothesis evaluated was that Meq heterodimers are involved in Meq induced 
transformation via a c-Jun activation pathway and that Meq homodimers are involved in 
regulation of viral latency and reactivation. This hypothesis was tested by the generation 
of recombinant Meq mutant viruses (rMd5-MeqGCN and rMd5-MeqFos) expressing 
chimeric meq genes (MeqGCN and MeqFos) that exclusively form homodimers or 
heterodimers, respectively. In addition, a third recombinant virus was recovered rMd5-
MeqFos/GCN containing one copy of each MeqGCN and MeqFos in order to study the 
contribution of both Meq homodimers and heterodimers in MDV pathogenesis. The 
DNA binding, transactivation/repression and transforming properties of the chimeric 
meq genes were tested in vitro and cytolytic and transforming infection of the 
recombinant viruses evaluated in vivo.  
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Both MeqGCN and MeqFos retained DNA binding and 
transactivation/repressive functions in vitro. However, MeqFos required exogenous 
expression of c-Jun to transactivate the meq promoter while Meq and MeqGCN did not. 
This supports that MeqFos dimerization was restricted to c-Jun. In addition, while 
MeqGCN retained the ability to repress the pp38/14 promoter and 3X-Ori, repression 
was less than Meq. Unexpectedly, MeqFos was able to repress pp38/14 promoter and 
3X-Ori, even though Meq/c-Jun dimers were reportedly unable to bind the Ori sequence 
(42). ChIP assays confirmed that MeqFos bound the 3X-Ori. However, since previous 
characterization of Meq binding sites utilized bacterial expressed proteins and EMSA 
analysis (42), cooperation of other unknown cellular factors may have contributed to the 
ability of MeqFos to bind the 3X-Ori. Furthermore, although other Meq binding sites 
within the pp38/pp14 promoter have not been defined by site-directed mutagenesis, AP-
1 sites are reported to be located in the bidirectional promoter, providing a potential 
binding site for MeqFos and c-Jun. Therefore, transcriptional repression by Meq may 
involve displacement of activating factors at the bidirectional promoter by binding these 
elements.  
Both MeqGCN and MeqFos exhibited reduced transforming potential in vitro as 
assessed by colony formation by soft agar. Interestingly, Meq and MeqFos expression 
was reduced in selected cells compared to MeqGCN, implicating that Meq and MeqFos 
expression may have unfavorable effects and only a subset of cells can support high Meq 
expression levels. More importantly, although rMd5-MeqGCN, rMd5-MeqFos and 
rMd5-MeqFos/GCN replicated in infected chickens, they are less pathogenic than 
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parental rMd5. Recombinant virus Md5-MeqGCN was non-oncogenic while rMd5-
MeqFos induced preneoplastic nerve lesions in 50% of infected chickens.  Although 
rMd5-MeqFos/GCN was more oncogenic with 20% and 60% of infected chickens 
containing neoplastic and preneoplastic nerve lesions, respectively, visceral tumors were 
not observed. Furthermore, chickens infected with rMd5 had to be euthanized or died on 
average four-five weeks PI. In contrast, all rMd5-MeqFos chickens survived the 8-week 
experiment except for two early nonspecific deaths.  While only two chickens exhibited 
paralysis from the rMd5-MeqFos/GCN group and were euthanized 5 and 7 weeks PI 
while the remaining chickens survived the duration of the experiment.  
This indicates that although Meq homodimers and heterodimers contribute to 
MDV transformation, the mutations in the leucine zipper resulted in viruses that are not 
as pathogenic as parental Md5. Revertant viruses from both rMd5-MeqGCN and rMd5-
MeqFos had restored parental phenotypes, confirming that the phenotypic differences 
observed with rMd5-MeqGCN and rMd5-MeqFos were due to the leucine zipper 
mutations. Revertant viruses that were recovered by plaque purification contained one 
copy of the mutant gene either meqGCN or meqFos and the parental meq gene. 
Interestingly, the revertant virus isolated from an rMd5-MeqGCNR infected chicken 
(only one was tested) contained both parental meq genes, while virus isolated from three 
out of three chickens infected with rMd5-MeqFos retained one copy of each meqFos and 
meq, thus implying that the meqGCN retained no advantage for the replicating virus, 
rMd5-MeqGCNR, while the meqFos gene still retained some function and was retained 
in the viral genome of rMd5-MeqFosR.  
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Since Meq has been shown to dimerize with ATF/CREB family members (42) 
and since the leucine zipper region of MeqFos should be restricted to interactions with 
Jun family members, it is possible that Meq dimerization with ATF/CREB family is also 
involved in MDV pathogenesis. As it has been shown that Jun/ATF2 interactions are one 
component involved in c-Jun transformation along with Jun/Jun and Jun/Fos dimers (27, 
34, 81). In addition, p53 and Rb are reported to interact with Meq and both of these 
putative binding sites are near the leucine zipper (36, 45). However, soft agar assays 
were performed in DF-1 cells that do not express p53 (36) therefore at least the loss of 
this interaction would not have influenced anchorage independent growth in DF-1 cells.  
However, the putative binding site for Rb is adjacent to the leucine zipper and although 
this motif was not changed, it remains possible that the interaction could have been 
disrupted.  
Lastly, we evaluated reactivation from latency from chickens infected with 
rMd5, rMd5-MeqGCN, rMd5-MeqFos and rMd5-MeqFos/GCN. All viruses but rMd5 
showed some deficiency in reactivation. However, these results cannot be fully 
confirmed without some assessment of viral load. But interestingly, pp38 expression was 
detected in PBMC’s from infected chickens and was only detected in dividing cells. This 
observation is interesting because in latent infection none to only a subset of viral 
proteins are expressed. In some cases, as has been described in latent EBV infected 
memory B-cells only EBNA1 is detected in dividing cells. EBNA1 is responsible for 
ensuring that the viral genome is segregated to daughter cells, and is localized in the 
nucleus (28). The pp38 expression was observed primarily in the cytoplasm of PBMC’s 
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so it is unclear as to it’s function in dividing cells but detection of it’s expression 
supports that these cells were latently infected and not reactivating virus.  
Future studies 
 Even though the c-Fos leucine zipper is well characterized allowing dimerization 
with the Jun family of bZIP proteins only, further evaluation of the dimerization 
properties of MeqFos should be pursued.  Luciferase assays indicate that MeqFos 
heterodimerizes with c-Jun, but future experiments designed to test if MeqFos 
exclusively heterodimerizes should be performed. EMSA analysis of in vitro 
transcription/translated products or bacterial expressed proteins has been utilized to 
study the DNA binding and dimer formation for other bZIP proteins (15, 26, 63). This 
same approach would be useful for testing the dimerization properties of MeqFos 
because it would test if MeqFos/MeqFos dimers form and bind the Ori sequence 
independently of other cellular factors, aiding in the interpretation the described ChIP 
assay results.  
This work demonstrated that both MeqGCN and MeqFos have reduced ability to 
transform and suggests that other cellular factors, ATF/CREB, p53, Rb, or other 
unknown cellular factors are necessary for full transformation by Meq. As a first step, 
the expression of CREB/ATF members in MDV transformed cells could be evaluated 
and coimmunoprecipitation assays performed to test possible dimerization between Meq 
and CREB/ATF members. Similar approaches with p53 and Rb could be performed. If 
an association is found, these experiments could be followed by using cells expressing 
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Meq, in proliferation assays, soft agar assays, assays to assess apoptosis, and siRNA 
targeting the proposed cooperating protein.  
Global analysis of Meq binding sites within the MDV genome and chicken 
genome would be a great tool for identifying Meq target genes. Chicken genome ChIP 
arrays are now available and an MDV tailored ChIP array could be produced. This 
would be a useful tool to detect Meq binding sites in MDV transformed cells, and could 
be applied to MDV transformed cells treated with sodium butyrate to induce 
reactivation.  Comparisons of the Meq binding sites in latent/transforming infection and 
lytic infection would provide a global assessment of Meq binding sites.  
Further work characterizing the transcriptional region of Meq would expand 
current knowledge of MDV transformation. Another possibility for the decrease in 
pathogenicity observed in rMd5-Meq/GCN and rMd5-Meq/Fos viruses is that another 
contributing viral factor may have been altered due to the leucine zipper mutations. 
Recently, a novel Meq splice variant has been identified in the Meq region (55). For this 
particular splice variant, the splice donor site is located the leucine zipper region and the 
splice acceptor site is at the C-terminus of Meq (55). Although Meq expression 
predominates over this splice variant in MDV transformed cells it may also have a 
contributing role in MDV transformation or may have a role in reactivation, as the 
leucine zipper mutant viruses described in this work displayed impaired reactivation.  
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